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Abstract 
Regulation of isoprenoid precursor pathways in Listeria monocytogenes 
by 
Eric David Lee 
Doctor of Philosophy in Infectious Diseases and Immunity 
University of California, Berkeley 
Professor Daniel A. Portnoy, Chair 
 
 Listeria monocytogenes is a facultative, Gram-positive intracellular pathogen that 
is also a model organism for studying bacterial pathogenesis. Much of the appeal of 
using L. monocytogenes as a model organism derives from the fact that much of the 
knowledge gained from studying L. monocytogenes pathogenesis or metabolism can be 
applied to other pathogens that are more difficult to work with or manipulate. However, 
the unique aspects of L. monocytogenes biology are equally fascinating and still shed 
light on the host cell processes that help protect against infections.  
 
 Isoprenoids are a diverse class of compounds produced by all forms of life and 
are synthesized from essential precursors derived from either the mevalonate pathway 
or the nonmevalonate pathway. Most organisms have one pathway or the other, but L. 
monocytogenes is unique because it encodes all of the genes from both pathways. 
Other scientists reported that the mevalonate pathway was essential for growth, but 
here we report that the nonmevalonate pathway was sufficient for growth anaerobically. 
Deleting the mevalonate pathway gene hmgR (∆hmgR) impaired bacterial growth in all 
L. monocytogenes strains studied, but the laboratory strain 10403S grew significantly 
slower than two lineage I strains, FSL N1-017 and HPB2262 Aureli 1997. The faster 
anaerobic growth of the lineage I strains was initially traced to a difference in the 
nonmevalonate pathway enzyme GcpE, and then chimeric proteins were constructed to 
precisely identify the molecular basis of this phenotype. Three amino acid residues, 
K291T, E293K, and V294A were shown to be necessary and sufficient to increase the 
anaerobic growth rate of 10403S ∆hmgR. However, these mutations did not map to 
GcpE in a way that provided any obvious mechanistic insights to how the enzyme 
function was altered. Even though the nonmevalonate pathway was found to function 
anaerobically, we were unable to identify conditions where deleting the nonmevalonate 
pathway impaired L. monocytogenes growth of any strain. Given the fitness cost of 
maintaining all seven genes in the nonmevalonate pathway, it is likely that there are yet 
unidentified anaerobic growth conditions that require the nonmevalonate pathway. This 
work showed that, contrary to previous reports, the mevalonate pathway is not essential 
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for L. monocytogenes growth anaerobically, although it is still essential for growth 
aerobically. 
 
 After finding specific mutations in GcpE that altered growth, we were also 
interested in understanding the broader networks regulating the nonmevalonate 
pathway in L. monocytogenes. The difference in anaerobic growth rates between 
10403S ∆hmgR and lineage I ∆hmgR mutants indicated that it could be possible to find 
suppressor mutations that increased 10403S ∆hmgR growth rate. 10403S ∆hmgR 
cultures were passaged anaerobically, and fast-growing suppressor mutants began 
arising after three passages, which was noted by the observation that cultures initially 
required four or five days to reach stationary phase, but later only required two days to 
reach stationary phase. Whole genome sequencing of these cultures identified 
mutations in several genes, but the most common mutations were in the histidine kinase 
of a two-component system LisRK. We demonstrated that the suppressor mutations 
altered rather than disrupted LisRK signaling, but were unable to identify specific genes 
in the regulon that were responsible for the increased rate of anaerobic growth. This 
work showed that multiple mutations can be made that alter the rate of L. 
monocytogenes growth using the nonmevalonate pathway. The previously identified 
mutations in GcpE likely directly change enzyme kinetics, allowing for increased flux 
through the nonmevalonate pathway, but the additional mutations identified here likely 
change gene expression levels or alter metabolite concentrations at points upstream or 
downstream of the nonmevalonate pathway itself.
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Chapter 1 
 
An introduction to Listeria monocytogenes 
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1.1 Listeria monocytogenes, an intracellular pathogen 
 
Listeria monocytogenes is a Gram-positive, facultative intracellular pathogen that 
grows in diverse environments. During infection, L. monocytogenes is taken up by 
professional phagocytic cells or induces its own uptake into nonphagocytic cells. After 
entering a cell, the virulence factor Listeriolysin O (LLO) forms a pore in the host cell 
vacuole, allowing L. monocytogenes to escape the vacuole and spread to the host 
cytosol (1). Once L. monocytogenes reaches this replicative niche, it rapidly proliferates, 
growing at almost the same rate in the cytosol as it does in rich media. It then secretes 
the protein ActA, which polymerizes host actin and allows the bacterium to propel itself 
into neighboring cells to continue replicating (Fig. 1.1) (2). 
 
Due to its fast doubling time, the relative ease of genetic manipulation, and the 
wide variety of in vitro and in vivo assays to analyze virulence, L. monocytogenes is a 
model organism for understanding bacterial pathogenesis (3). The conserved set of 
host pathways exploited by many bacterial pathogens has meant that studying L. 
monocytogenes has shed light on the strategies used by many clinically significant 
intracellular pathogens such as Chlamydiae, Salmonellae, and Mycobacterium 
tuberculosis (4,5). Outside of pathogenesis, L. monocytogenes has also contributed to 
our broader understanding of immunology and cancer biology (6). 
 
 
Figure 1.1. The intracellular L. monocytogenes life cycle.  
L. monocytogenes possesses multiple virulence factors that allow it to enter cells and 
spread cell-to-cell. Figure from reference (3). 
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1.2 Isoprenoid precursor biosynthesis pathways in bacteria 
 
The isoprenoid precursor molecules isopentenyl pyrophosphate and dimethylallyl 
pyrophosphate are essential in all cells (7). These precursors are the building blocks for 
isoprenoids, a diverse class of compounds containing more than 30,000 unique 
molecules. The vast majority of organisms produce these molecules using one of two 
pathways: the mevalonate pathway or the nonmevalonate pathway (also referred to as 
the DXP pathway). Mammals only have the mevalonate pathway (8), but it is of clinical 
significance because the rate-limiting enzyme of the mevalonate pathway is the target 
of statins, cholesterol drugs used by millions of people on a daily basis. ln contrast to 
mammals, bacteria have both pathways in a fairly even distribution (9). Gram-negative 
bacteria have a slight bias towards the nonmevalonate pathway and Gram-positive 
bacteria have a slight bias towards the mevalonate pathway, but why this bias exists is 
not clearly understood.  
 
L. monocytogenes is unique because it contains genes encoding for both the 
mevalonate and the nonmevalonate pathways (10). It is reported that the mevalonate 
pathway is essential, while the nonmevalonate pathway has little or no apparent 
function. We sought to understand why both pathways exist in L. monocytogenes if only 
the mevalonate pathway is used for growth. Furthermore, the nonpathogenic species 
Listeria innocua is believed to have evolved from L. monocytogenes (11), but has an 
incomplete nonmevalonate pathway. This raised the question of whether the 
nonmevalonate pathway has a role in L. monocytogenes pathogenesis, because it has 
maintained the pathway and was lost in L. innocua. 
 
1.3 Bacterial small molecules and the innate immune system 
 
 The mechanisms by which L. monocytogenes invades a host cell, escapes a 
vacuole, and spreads cell-to-cell have been well-characterized (3). However, there are 
still unresolved questions about how a host cell recognizes L. monocytogenes, and the 
strategies L. monocytogenes uses to avoid host detection. Previous studies from the 
Portnoy lab showed that the small molecule cyclic-di-AMP is produced and secreted by 
L. monocytogenes, and is then recognized by the mammalian protein Stimulator of 
Interferon Genes (STING) (12,13). Activation of STING induces Type I interferons and 
seems to inhibit cell-mediated immunity against L. monocytogenes (14). This discovery, 
along with several others outside of the lab, raised questions about whether other 
nonpeptidic antigens were produced by bacteria and what impact they had on the host 
immune system (15). Indeed, studies on MAIT cells and their cognate activating ligand, 
an intermediate of bacterial riboflavin biosynthesis, have helped reveal the complex 
functions of innate-like cells in the immune system (16). Furthermore, a huge number of 
novel small molecules have recently been discovered (17), sparking excitement that 
bacterial small-molecule ligands may have important unrecognized functions in both 
bacterial physiology and the innate immune system. 
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1.4 (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate and Vg9Vd2 T-cells  
 
 (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) is an intermediate 
molecule of the nonmevalonate pathway that potently activates innate-like Vg9Vd2 T-
cells. Vg9Vd2 T-cells are a subset of gd T-cells that exist in humans and nonhuman 
primates, along with a number of other organisms, but crucially, are not found in mice 
(18). In contrast to conventional T-cells, which recognize antigens using their T-cell 
receptor after the antigen is presented on an MHC molecule, Vg9Vd2 T-cells recognize 
conformational changes in the butyrophilin protein BTN3A1 (19,20). BTN3A1 is a 
transmembrane protein expressed on most professional and nonprofessional antigen 
presenting cells, and is activated by multiple natural ligands including HMBPP and the 
downstream isoprenoid precursors, IPP and DMAPP. However, it is estimated to be 
approximately 10,000 times more sensitive to HMBPP than IPP or DMAPP, likely 
because IPP and DMAPP are ligands naturally produced in host cells (10). HMBPP, 
IPP, DMAPP, and synthetic ligands that mimic HMBPP are chemically similar in their 
pyrophosphate group, and thus these compounds as a group are termed 
phosphoantigens. When BTN3A1 binds phosphoantigen molecules on the intracellular 
domain, a conformational change is induced extracellularly, which allows the Vg9Vd2 T-
cell receptor to bind and for the cell to become activated (Fig. 1.2).  
 
 
 
Figure 1.2. Simplified diagram of phosphoantigen-induced Vg9Vd2 T-cell 
activation.  
Phosphoantigens produced by bacteria or transported into the cell bind the intracellular 
domain of BTN3A1. This causes an extracellular conformational change that, in 
combination with an unknown costimulatory Protein X, allows for Vg9Vd2 T-cell binding 
and activation. 
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Vg9Vd2 T-cells are activated by infection with HMBPP-producing microorganisms 
or synthetic ligands, at which point they proliferate and perform a wide variety of 
functions. They have been found to have direct cytotoxic activity against cells infected 
with bacterial pathogens, and are also capable of producing cytokines to alter the local 
immune microenvironment in response to infection (21–23). Human studies have 
observed that Vg9Vd2 T-cells can expand to constitute up to 50% of all T-cells in the 
peripheral blood during bacterial infections, and there are strong correlations between 
high Vg9Vd2 T-cell levels and positive outcomes in some types of cancers (24). 
Nonetheless, their precise role in immunity has been difficult to elucidate as their 
absence in mice or any other genetically tractable model organism has made it very 
challenging to use typical immunological approaches (25–27). 
 
Despite the absence of easily tractable model systems, a remarkable series of 
studies have been conducted using nonhuman primates to examine Vg9Vd2 T-cell 
function during infection. These studies demonstrated that a strain of L. monocytogenes 
containing a constitutively activate mutation in the master virulence regulator PrfA 
(PrfA*) increases humoral and cellular immune responses in primates (28). They next 
showed that vaccination with an attenuated L. monocytogenes strain ∆actA prfA* 
activates Vg9Vd2 T-cells in vivo. Furthermore, if the activated Vg9Vd2 T-cells are 
purified from peripheral blood, they are capable of specifically targeting and killing L. 
monocytogenes-infected cells in vitro (29). Vg9Vd2 T-cell activation was shown to be 
dependent on bacterial HMBPP production, because vaccination with a strain that does 
not produce HMBPP (∆actA prfA* ∆gcpE) activates fewer Vg9Vd2 T-cells than ∆actA 
prfA* (30). Finally, they demonstrated that activated Vg9Vd2 T-cells reduced bacterial 
burdens in macaques infected with M. tuberculosis, both after ex vivo activation of 
Vg9Vd2 T-cells with purified HMBPP (31) or after the animals were vaccinated with an 
HMBPP-producing strain of L. monocytogenes (32). 
 
This work showed that L. monocytogenes HMBPP production can increase 
control of M. tuberculosis, but we were curious whether it would be possible to 
manipulate the nonmevalonate pathway to produce even more HMBPP than is 
endogenously produced by L. monocytogenes 10403S. However, that question required 
a deeper understanding of the nonmevalonate pathway function in L. monocytogenes, 
which became the starting point for this work. 
 
1.5 From model organism to cancer immunotherapy: bugs as drugs 
 
 L. monocytogenes is a model organism of bacterial pathogenesis, but is also 
known to induce a potent CD8+ T-cell response against both bacterial antigens and 
artificial neoantigens expressed by virulent or attenuated strains (33). This discovery 
ultimately led to an effort to examine whether L. monocytogenes could be used as a 
cancer immunotherapy platform. Subsequent clinical trials provided a unique 
opportunity to gain insight into Vg9Vd2 T-cell responses after L. monocytogenes 
treatment. These studies observed that Vg9Vd2 T-cells proliferated after every 
administration of the L. monocytogenes vaccine, and unexpectedly, did not contract or 
express typical exhaustion markers despite repeated exposure to bacteria and HMBPP 
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(unpublished data, Aduro Biotech). Additionally, Vg9Vd2 T-cells were the only cell 
subset that significantly increased in response to treatment, while B cells, NK cells, and 
both CD4+ and CD8+ T-cells remained constant in all patients. 
 
 As a result, we were curious to better understand the function Vg9Vd2 T-cells in 
the human immune system and, at a more basic level, what role the nonmevalonate 
pathway has in L. monocytogenes bacterial physiology. In the context of human 
infections or therapies, how does HMBPP production and activation of Vg9Vd2 T-cells 
influence the outcome of primary infections and the development of adaptive immunity? 
Does a strong cytotoxic and innate-like response from Vg9Vd2 T-cells help control an 
infection, but does that come at the cost of long-term immunity? Answering these 
questions would have significant implications for all HMBPP-producing bacterial 
pathogens. 
 
A second line of questioning is relevant for understanding L. monocytogenes 
metabolism and pathogenesis. L. monocytogenes infects a broad range of primates, 
ruminants, and lagomorphs, the vast majority of which are not known to have an 
HMBPP-responsive cell type. It seemed very unlikely that any growth advantage 
conferred by activating Vg9Vd2 T-cells in primates would exert a strong enough 
selective pressure to maintain the nonmevalonate pathway. Therefore, we wanted to 
understand if the nonmevalonate pathway functioned at all as a means of growth, and 
whether a non-immunological role for the pathway impacted bacterial pathogenesis.  
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Chapter 2 
 
The nonmevalonate pathway of isoprenoid biosynthesis supports anaerobic 
growth of Listeria monocytogenes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sections of this chapter were submitted for publication as: 
Lee, E.D., Navas, K.I., Portnoy, D.A. (2019). The nonmevalonate pathway of isoprenoid 
biosynthesis supports anaerobic growth of Listeria monocytogenes. 
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2.1 Summary of results 
Isoprenoids are an essential and diverse class of molecules present in all forms 
of life that are synthesized from an essential common precursor derived from either the 
mevalonate pathway or the nonmevalonate pathway. Most bacteria have one pathway 
or the other, but the Gram-positive, facultative intracellular pathogen Listeria 
monocytogenes is unusual because it encodes all the genes for both pathways. While 
the mevalonate pathway has previously been reported as essential, here we 
demonstrate that the nonmevalonate pathway can support growth of strains 10403S 
and EGD-e, but only anaerobically. L. monocytogenes lacking the gene hmgR, the rate-
limiting enzyme of the mevalonate pathway, had a doubling time of four hours in 
anaerobic conditions in contrast to the 45-minute doubling time of WT. In contrast, 
deleting hmgR in two clinical isolates resulted in mutants that grew significantly faster, 
doubling in approximately two hours anaerobically, although they still failed to grow 
under aerobic conditions without mevalonate. The difference in anaerobic growth rate 
was traced to three amino acid changes in the nonmevalonate pathway enzyme GcpE, 
and these changes were sufficient to increase the growth rate of 10403S to the rate 
observed in the clinical isolates. Despite an increased growth rate, virulence was still 
dependent on the mevalonate pathway in 10403S strains expressing the more active 
GcpE allele. 
 
2.2 Introduction 
Isoprenoids represent the largest family of compounds present in all living 
organisms, used for a wide variety of processes including cell wall synthesis, electron 
transport, and maintaining membrane fluidity (7). Isoprenoids are derived from the 
essential isoprenoid precursor molecules isopentenyl pyrophosphate (IPP) or 
dimethylallyl pyrophosphate (DMAPP). These precursors are synthesized by two 
distinct pathways, the mevalonate pathway and the nonmevalonate pathway (Fig. 1A). 
While mammals all use the mevalonate pathway (8), bacteria usually encode genes for 
only one of the two pathways (9). In rare instances bacteria lack both pathways, such as 
the obligate intracellular bacteria Rickettsia parkeri, but these bacteria depend on the 
host cell as a source for isoprenoid precursors (34). Listeria monocytogenes is a Gram-
positive, facultative intracellular pathogen that, unlike most bacteria, has the genes for 
both the mevalonate and the nonmevalonate pathways (10). Work from others reported 
that the rate-limiting enzyme of the mevalonate pathway, HmgR, is essential in L. 
monocytogenes EGD-e, as strains lacking hmgR cannot grow unless supplemented 
with mevalonate in the growth media (35,36). Deleting either of the last two enzymes in 
the nonmevalonate pathway, GcpE or LytB, had no impact on growth in vitro and a 
negligible effect on virulence (36).  
While it is curious that L. monocytogenes has both isoprenoid precursor 
pathways, interest in these pathways also stems from observations that an intermediate 
molecule of the nonmevalonate pathway, (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate (HMBPP), activates Vg9Vd2 T-cells, an innate-like T-cell subset found in 
humans and non-human primates, but not in mice (37). Upon activation by 
microorganisms with the nonmevalonate pathway or synthetic ligands, Vg9Vd2 T-cells 
proliferate, produce proinflammatory cytokines, and have cytotoxic activity against cells 
presenting HMBPP (20). Vg9Vd2 T-cells have a broad role communicating with innate 
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and adaptive immune cells to coordinate responses to bacterial infections, but it has 
been difficult to gain a mechanistic understanding of their functions due to the challenge 
of developing an appropriate model system (26,27).  
L. monocytogenes is being developed as a cancer vaccine platform, using a live-
attenuated recombinant bacterial strain to stimulate CD8+ T-cell responses (33). Despite 
impressive results in mice, human clinical trials have shown promising, but limited 
responses to L. monocytogenes-based treatments. Given the potential role of Vg9Vd2 
T-cells in responses to HMBPP-producing L. monocytogenes in humans, we were 
interested in further understanding isoprenoid precursor pathways in strain 10403S, the 
bacterial strain used for these studies. Additionally, we were intrigued by the 
observation that L. monocytogenes contains both pathways, despite no reported 
function for the nonmevalonate pathway.  
In this study, we further examined the role of the mevalonate and nonmevalonate 
pathways for L. monocytogenes growth and pathogenesis. Additionally, the 
nonmevalonate pathway was examined in two L. monocytogenes strains, FSL N1-017 
which was isolated from trout brine (38) and HPB2262 Aureli 1997 (HPB2262) which 
was isolated from an outbreak of gastroenteritis (39). These isolates were chosen 
because they are in L. monocytogenes lineage I, which are far more prevalent in human 
listeriosis cases and are genetically distinct from 10403S and EGD-e, which are in 
lineage II (40). We found that the mevalonate pathway was not essential for growth 
when ∆hmgR mutants were cultured anaerobically, as strains with only the 
nonmevalonate pathway grew in the absence of mevalonate. Additionally, three amino 
acid differences found in the lineage I strains could significantly alter GcpE function in L. 
monocytogenes strain 10403S, resulting in improved anaerobic growth compared to WT 
L. monocytogenes. These results demonstrate that either the mevalonate pathway or 
the nonmevalonate pathway is sufficient for L. monocytogenes growth in anaerobic 
conditions. 
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2.3 Results 
 
2.3.1 L. monocytogenes 10403S does not require the mevalonate pathway for 
anaerobic growth. 
Consistent with previous reports (36), a 10403S strain lacking hmgR (10403S 
∆hmgR) was unable to grow on BHI agar unless supplemented with mevalonate (Fig. 
1B). In liquid media the growth of 10403S ∆hmgR was fully restored with 1 mM 
mevalonate or if hmgR was complemented on an integrating plasmid pPL2 (Fig. 1C).  
The last two enzymes of the nonmevalonate pathway, GcpE and LytB, contain 
[4Fe-4S] iron-sulfur clusters (FeS clusters) (41,42). In the presence of oxygen, FeS 
clusters can be oxidized, leaving a catalytically inactive [3Fe-4S]1+ FeS cluster (43). 
GcpE and LytB (also referred to as IspG and IspH, respectively) are particularly oxygen-
labile in other organisms, since the FeS cluster is solvent-exposed (44–46). We 
hypothesized that L. monocytogenes growth using the nonmevalonate pathway might 
be promoted anaerobically, due to decreased oxidation of GcpE or LytB FeS clusters. 
Indeed, strains lacking hmgR grew in the absence of mevalonate, although they 
exhibited a severe increase in doubling time, increasing from 43 mins aerobically with 
mevalonate to approximately four hours anaerobically without mevalonate (Fig. 2A). 
Additionally, 10403S ∆hmgR formed a visible colony overnight on BHI agar 
supplemented with mevalonate, while it required four to five days to form similarly sized 
colonies anaerobically without mevalonate. Growth was dependent on the 
nonmevalonate pathway, as mutants in both pathways (10403S ∆hmgR∆gcpE and 
10403S ∆hmgR∆lytB) lost viability over the course of the anaerobic experiment (Fig. 2A) 
and did not form colonies on BHI agar anaerobically without mevalonate. 
To examine whether anaerobic growth was a result of acquired suppressor 
mutations, the plating efficiency of strains was examined in aerobic and anaerobic 
conditions after overnight cultures were plated with or without mevalonate or oxygen. 
Aerobically, no 10403S ∆hmgR colonies grew unless the media contained mevalonate. 
Anaerobically, equal numbers of bacteria were recovered without mevalonate, relative 
to media with mevalonate (Fig. 2B). Collectively, these data indicate that the 
nonmevalonate pathway supports growth in the absence of the mevalonate pathway. 
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Figure 2.1. The mevalonate pathway is essential for aerobic growth.  
A. Abbreviated diagram of L. monocytogenes isoprenoid precursor pathways. See 
reference (10) for full pathway. B. Disk diffusion assay using 10 µL of 1 M mevalonate 
on a BHI agar plate spread with WT or 10403S ∆hmgR, demonstrating mevalonate-
dependent growth. White bar is 20 mm. C. Aerobic BHI growth curve of WT, 10403S 
∆hmgR, and 10403S ∆hmgR with hmgR gene on the integrating plasmid pPL2. 10403S 
∆hmgR was grown in BHI supplemented with the indicated concentrations of 
mevalonate. 
 
 
2.3.2 Growth phenotype of mevalonate pathway mutants in other L. 
monocytogenes strains. 
Previous work on L. monocytogenes isoprenoid precursor pathways was 
conducted using strain EGD-e, where the mevalonate pathway was found to be 
essential (36). However, the authors did not examine anaerobic growth of their 
mevalonate pathway mutant, so we were curious whether any strain-specific growth 
differences existed between EGD-e and 10403S. The mevalonate pathway was deleted 
in EGD-e (EGD-e ∆hmgR), and two lineage I strains, L. monocytogenes FSL N1-017 
(FSL ∆hmgR) and L. monocytogenes HPB2262 (HPB ∆hmgR). Both lineage I strains 
doubled in approximately two hours when hmgR was deleted, which was significantly 
faster than 10403S ∆hmgR (Fig. 2C). EGD-e ∆hmgR grew on BHI agar anaerobically 
without mevalonate (Fig. S1), but did not grow in liquid culture, preventing the 
measurement of a doubling time.  
To determine whether there was a genetically encoded basis for the observed 
differences in growth, we compared the 5’ UTRs and coding sequences of 10403S, FSL 
N1-017, and HPB2262 for each gene in the nonmevalonate pathway. Three genes, dxr, 
ispE, and ispF, were identical among all three strains. The 5’ UTR of ispD differed 
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between strains, but no growth differences were observed when the genes for ispD or 
lytB from the lineage I strain were introduced into 10403S ∆hmgR. However, strains 
complemented with gcpE from either FSL N1-017 or HPB2262 grew significantly faster 
than strains with 10403S gcpE (Fig. 2D). 
 
 
Figure 2.2. The nonmevalonate pathway is sufficient for anaerobic growth.  
A. Anaerobic BHI growth curve of 10403S ∆hmgR compared to mutants in both 
pathways (10403S ∆hmgR∆gcpE and 10403S ∆hmgR∆lytB). B. CFUs measured after 
plating aerobic 10403S ∆hmgR cultures in indicated oxygen or mevalonate conditions. 
C. Anaerobic growth of 10403S ∆hmgR compared to ∆hmgR mutants from indicated L. 
monocytogenes strains. D. Anaerobic growth of 10403S ∆hmgR∆gcpE with gcpE from 
indicated strains on pPL2, compared to 10403S ∆hmgR with gcpE on the chromosome. 
 
 
 
2.3.3 Three residues in GcpE account for differences in anaerobic growth.  
gcpE chimeric proteins were constructed to more precisely identify the molecular 
origin of the growth differences between 10403S and the lineage I strains. First, the 5’ 
UTRs and coding sequences from each strain were exchanged and introduced into 
10403S ∆hmgR∆gcpE. Only strains complemented with the protein coding sequence 
from either lineage I strain grew significantly faster, even if expressed downstream of 
the 10403S 5’ UTR (Fig. 3A). Twelve amino acid differences exist in GcpE between 
10403S and the lineage I strains. A chimeric protein was constructed containing the N-
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terminal portion of 10403S and the C-terminal portion of the FSL N1-017 protein, from 
amino acid 251 (Fig. 3B). The C-terminal end was chosen because it contained all four 
residues involved with FeS cluster coordination and the majority of the catalytic 
residues. Strains complemented with the chimeric strain grew as well as strains with the 
entire FSL N1-017 gene (Fig. 3C).  
The C-terminal end of GcpE has nine differences between the lineage I strains 
and 10403S, the majority of which are located in three distinct areas, therefore we 
focused on those changes. Two pairs of mutations, GcpEI343V/D344E and GcpEF357Y/V359E, 
had no impact on anaerobic growth (Fig. 3D). Mutating three other residues in 
combination, GcpEK291T/E293K/V294A (GcpE*), significantly increased the growth rate of 
10403S ∆hmgR ∆gcpE while the single mutants of either GcpEK291T or GcpEV294A were 
not sufficient to increase (Fig. 4A). Furthermore, when the same GcpE* mutations were 
made on the chromosome rather than on a plasmid, the resulting strain (10403S 
∆hmgR gcpE*) had an identical anaerobic growth rate as FSL ∆hmgR (Fig. 4B). 
Given the distinct growth differences between 10403S ∆hmgR and 10403S 
∆hmgR gcpE*, we sought to understand how these mutations impacted protein function. 
The protein structure prediction program Phyre2 was used to generate a model of GcpE 
based on the crystal structure from Aquifex aeolicus (strain VF5). The predicted 
structure placed residues 291-294 in a loop distal from both the FeS cluster and the 
catalytic TIM barrel in the protein (Fig. 4C), providing little insight into the mechanism by 
which these mutations alter 10403S ∆hmgR gcpE* anaerobic growth.  
 
2.3.4 HMBPP quantification using high-performance liquid chromatography. 
Liquid chromatography-triple quadrupole mass spectrometry was then used to 
directly measure HMBPP levels in strains grown anaerobically (Fig. 2.4D). Deleting 
gcpE modestly reduced HMBPP, while it significantly increased after deleting lytB. L. 
monocytogenes 10403S produced a similar amount of HMBPP as EGD-e, but both 
clinical isolates produced more. Despite the significantly different growth rates of 
∆hmgR and ∆hmgR gcpE*, the two strains produced similar amounts of HMBPP.  
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Figure 2.3. Increased growth of lineage I strains is caused by changes in GcpE 
coding sequence.  
A. Anaerobic growth of 10403S ∆hmgR∆gcpE complemented with the gcpE coding 
sequence from different strains, all expressed from the 10403S 5’ UTR. B. Sequence 
alignment of L. monocytogenes GcpE found in two lineage I strains and two laboratory 
strains. Listed residues indicate sequence differences relative to 10403S. C. Anaerobic 
growth of 10403S ∆hmgR, FSL N1-017 ∆hmgR, and 10403S ∆hmgR∆gcpE 
complemented with a GcpE chimera containing the N-terminal domain (amino acids 1-
250) from 10403S and the C-terminal domain from FSL N1-017 (amino acids 251-369). 
D. Anaerobic growth of 10403S ∆hmgR∆gcpE complemented with point mutations 
GcpEI343V/D344E or GcpEF357Y/V359E. 
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Figure 2.4. Point mutations fixing GcpE function increase anaerobic growth.  
A. Anaerobic growth of ∆hmgR∆gcpE complemented with GcpEK291T/E293K/V294A or point 
mutations GcpEK291T and GcpEV294A. B. Anaerobic growth of 10403S ∆hmgR, FSL N1-
017 ∆hmgR, and 10403S ∆hmgR with GcpEK291T/E293K/V294A mutation on the 
chromosome. C. Predicted GcpE structure generated with Phyre2 protein structure 
prediction software. Two GcpE dimers colored in green and cyan, with iron-sulfur cluster 
coordinating residues colored in purple and residues 291-294 colored in red. 
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2.3.5 Nonmevalonate pathway function does not alter L. monocytogenes 
virulence in mice. 
Previous studies found minimal virulence defects when the nonmevalonate 
pathway was mutated in EGD-e (35,36,47), so we were curious whether 10403S had a 
similar phenotype. No significant virulence defects were observed in an IV infection (Fig. 
S2A) or a five-day oral infection (Fig. S2B) with nonmevalonate pathway mutants. 
Furthermore, there were no differences in virulence between 10403S ∆hmgR and 
10403S ∆hmgR gcpE* in an IV infection (Fig. 5A) and or infection model (Fig. 5B), as 
both had significant virulence defects, but were not different from each other.  
We hypothesized that the nonmevalonate pathway may have a minor 
contribution to growth, and if so, differences might become apparent in a long-term oral 
infection model. During an oral infection, systemic bacterial dissemination adds an 
additional layer of complexity for understanding bacterial survival in the gut. Bacteria 
that spread from the gut can colonize the gallbladder and reseed the intestinal tract (48–
50). This reservoir of bacteria is then the principal source of bacteria shed in the feces, 
rather than bacteria that have only survived in the anaerobic environment of the 
gut. Therefore, to prevent systemic dissemination and more closely examine long-term 
survival, a transposon (51) was used to disrupt the essential virulence factor listeriolysin 
O in our WT strain (10403S hly::Tn917), both nonmevalonate pathway deletions 
(10403S ∆gcpE hly::Tn917 and 10403S ∆lytB hly::Tn917) and the fast-growing GcpE 
mutant (10403S gcpE* hly::Tn917). After oral infection, L. monocytogenes CFUs in the 
feces decreased over time, but mice continued to shed detectable amounts of bacteria 
31 days post-infection (Fig. 5C). Previous studies show that mice stop shedding WT two 
weeks post infection in a streptomycin pretreatment model (52), so it was unexpected 
that all 10403S hly::Tn917 strains continued to be shed four weeks post infection. While 
small differences in the median CFUs shed from mice were noted, these changes did 
not rise to the level of statistical significance. These data suggest that the increased in 
vitro anaerobic growth with a GcpE* mutation does not impact bacterial survival when 
the bacteria are confined to the gut of mice.  
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Figure 2.5. L. monocytogenes virulence in mice does not change with increased 
nonmevalonate pathway growth.  
A. CFUs recovered from indicated organs one day after IV infection with indicated L. 
monocytogenes strains. Data show two independent experiments, with ten mice total for 
each strain, plotting medians and interquartile range. B. CFUs recovered from mice five 
days after oral infection with indicated L. monocytogenes strains. Data show two 
independent experiments, with ten mice total for each strain. C. CFUs recovered from 
pellets after oral infection with indicated L. monocytogenes strains. Plotted line is 
median CFUs from two independent experiments (10403S hly::Tn917, 10403S gcpE* 
hly::Tn917, n = 20; 10403S ∆gcpE, 10403S ∆lytB, n = 15) and shaded area is 
interquartile range. 
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2.4 Discussion  
The results of this study show that the L. monocytogenes mevalonate pathway 
was essential for growth aerobically and supports growth anaerobically, while the 
nonmevalonate pathway was sufficient for growth only anaerobically. This growth 
phenotype was observed in four L. monocytogenes strains, although strains FSL N1-
017 and HPB2262 lacking hmgR grew significantly faster than 10403S and EGD-e. 
Genetic approaches were used to identify three amino acid residues in the 
nonmevalonate pathway enzyme GcpE that were sufficient to eliminate differences in 
anaerobic growth between strains. A strain with GcpEK291T/E293K/V294A mutations grew 
more rapidly in pure culture, but did not have significantly altered growth phenotypes in 
mice.  
As a facultative anaerobe, L. monocytogenes substantially reprograms its 
metabolism in the absence of oxygen (53). We show that the nonmevalonate pathway 
functions anaerobically, but note that L. monocytogenes still grows faster using the 
mevalonate pathway. This implies that there may be unidentified anaerobic growth 
conditions where the nonmevalonate pathway is required or beneficial for growth. 
Aerobically, L. monocytogenes uses oxygen as a terminal electron acceptor to maintain 
NAD+/NADH ratios while pyruvate is converted to a variety of reduced (lactate, ethanol) 
and oxidized fermentation products (acetate, acetoin). Anaerobically, pyruvate 
represents the primary electron acceptor and consequently, the reduced fermentation 
product lactate predominates (54).  Reflecting these metabolic changes, pyruvate 
dehydrogenase is downregulated anaerobically and presumably, less acetyl-CoA is 
generated (53). The mevalonate and nonmevalonate pathways start with distinct 
molecules to generate isoprenoid precursors. The mevalonate pathway uses two 
molecules of acetyl-CoA, while the nonmevalonate pathway uses one molecule of 
pyruvate and one molecule of glyceraldehyde 3-phosphate. Under anaerobic conditions, 
the metabolic shift towards lactate fermentation may limit acetyl-CoA levels, or the 
acetyl-CoA that is present may need to be used for NAD+ regeneration. As a result, L. 
monocytogenes may use the nonmevalonate pathway anaerobically as an acetyl-CoA-
independent means of producing isoprenoid precursors. However, under conditions 
used in this study the mevalonate pathway was sufficient. 
We hypothesize that the nonmevalonate pathway fails to function aerobically in 
L. monocytogenes because GcpE and LytB are oxygen-labile, FeS cluster-containing 
enzymes. FeS clusters are essential metal cofactors in enzymes, but can be oxidized 
and lost in the presence of oxygen. As a result, organisms have developed mechanisms 
for protecting FeS clusters from oxidation, including multiple biosynthetic pathways to 
produce replacement FeS clusters for those damaged by oxidative stresses (55). Three 
distinct pathways for FeS cluster synthesis have been identified and designated as the 
Nif, Suf, and Isc systems (56). The Gram-negative bacteria Escherichia coli has both 
the Isc and Suf systems (57,58) while the Gram-positive model organism Bacillus 
subtilis and L. monocytogenes only have the Suf system. Isc and Suf genes are 
essential, but recent studies show that they are essential for synthesizing the FeS 
clusters in GcpE and LytB (59,60). B. subtilis only encodes the nonmevalonate 
pathway, but grows aerobically, which suggests that L. monocytogenes is fundamentally 
different from B. subtilis and may have a defect synthesizing FeS clusters which 
prevents it from using the nonmevalonate pathway anaerobically.  
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The crystal structure of L. monocytogenes GcpE has not been solved, but 
structures from other organisms point toward a mechanism by which mutations in GcpE 
may alter enzyme function (61–64). GcpE has two major domains, consisting of a 
catalytic TIM barrel at the N-terminal end, and an FeS cluster coordinated by three 
cysteine residues and one glutamic acid residue at the C-terminal end. The protein 
forms a homodimer consisting of two subunits aligned “head-to-tail.” This allows the 
FeS cluster of one subunit to catalyze reactions in the active site of the opposite 
subunit, but this mechanism requires the C-terminal domain to rotate significantly while 
“closing” on a ligand (63,65). We hypothesize that all three amino acid changes 
identified are necessary to alter enzyme kinetics and allow catalysis to proceed more 
quickly.  
Dozens of preclinical studies and clinical trials have used L. monocytogenes 
10403S as a vaccine vector for cancer immunotherapy (29,30,33,66–68). All the strains 
used in these studies produce HMBPP based on the observation that they stimulate 
Vg9Vd2 T-cells (30). Based on the results of this study, we predict that 10403S makes 
less HMBPP than the lineage I strains, although absolute HMBPP concentrations have 
not been directly measured. The role of Vg9Vd2 T-cells is still unclear, so it is difficult to 
determine whether cellular activation in response to HMBPP enhances or diminishes 
the efficacy of a L. monocytogenes-based vaccine in primates. However, characterizing 
HMBPP production in the presence of the mevalonate pathway and metabolically 
engineering 10403S to produce more HMBPP may be useful to improve our 
understanding of Vg9Vd2 T-cells and their role in vaccine development (69). 
The two L. monocytogenes isolates used in this study raise interesting questions 
about the relationship between nonmevalonate pathway and L. monocytogenes 
pathogenesis in humans. HPB2262 was isolated from an outbreak of febrile 
gastroenteritis caused by contaminated corn salad (39), but the symptoms of the 
outbreak were unique because the disease was almost exclusively noninvasive. In 
contrast, FSL N1-017 was isolated from trout in brine and is not associated with any 
human outbreaks. However, it is closely related to strain FSL R2-503 which is a clinical 
isolate from a different outbreak of gastroenteritis (38,70). It is possible that having a 
functional nonmevalonate pathway provides L. monocytogenes with a selective growth 
advantage in the human gut. Alternatively, they may have a greater capacity to produce 
HMBPP and stimulate Vg9Vd2 T-cells, which may trigger an immune response that 
contributes to disease (71). Separating causative versus correlative factors related to 
Vg9Vd2 T-cells would be challenging though, given the absence of animal models and 
likelihood that other genes in lineage I L. monocytogenes strains influence 
pathogenesis. 
A large number of clinically significant bacterial and protozoan pathogens such 
as Vibrio cholerae, Pseudomonas aeruginosa, Clostridium difficile, Mycobacterium 
tuberculosis, and Plasmodium species have the nonmevalonate pathway and produce 
HMBPP. However, the nonmevalonate pathway is essential for producing isoprenoid 
precursors in all of these organisms, making it extremely difficult to separate growth 
defects from virulence defects. In bacteria that encode both pathways, including 
Mycobacterium marinum (72) and several Streptomyces and Nocardia species (73), 
even less is known about isoprenoid pathways. By understanding the role of the 
nonmevalonate pathway in L. monocytogenes, it may be possible to metabolically 
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engineer other bacteria to intentionally manipulate Vg9Vd2 T-cell activation levels and 
improve adaptive immune responses to pathogens. 
 
2.5 Materials and Methods 
 
Construction of L. monocytogenes strains 
The L. monocytogenes strains used in this study are all derived from wild-type 
10403S (DP-L6253) unless otherwise noted and are listed in Table 1. Gene deletions 
were generated by allelic exchange using the plasmid pKSV7 (74). All L. 
monocytogenes strains were grown in brain heart infusion (BHI) broth supplemented 
with 5 g/L yeast extract, 1 g/L L-cysteine hydrochloride, and 0.001 g/L resazurin sodium 
salt, and media was supplemented with 1 mM mevalonate as needed to support the 
growth of auxotrophic ∆hmgR strains. Mevalonate was produced by hydrolyzing DL-
mevalonolactone (Sigma-Aldrich CAS Number 674-26-0) with 1 N NaOH at 37 ºC for 1 
hour, according to previously reported methods (35). Agar plates were incubated 
anaerobically using a BD GasPak EZ anaerobic pouch system (Cat no. 260683) and 
liquid cultures were incubated in an anaerobic chamber (Coy Laboratory Products) with 
an environment of 2% H2 balanced with N2. 
E. coli strains used in this study are listed in Table 2. For vector construction, 
plasmids were introduced into TOP10 E. coli (Invitrogen) or XL1 Blue E. coli 
(Stratagene). Plasmids were then transformed into SM10 E. coli and conjugated into L. 
monocytogenes. PCR was performed with KAPA HiFi DNA polymerase (Kapa 
Biosystems) or Q5 DNA polymerase (NEB). Positive clones were identified by 
performing colony PCRs using SapphireAmp Fast PCR Master Mix (Takara Bio) and 
verified by Sanger sequencing. 
 
Aerobic growth curves 
Strains were grown overnight at 37 ºC in filter-sterilized BHI and were 
supplemented with 500 µM mevalonate as necessary. Bacteria were washed with PBS 
and diluted in 20 mL fresh BHI to an optical density at a wavelength of 600 nm (OD600) = 
0.01. Cells were cultured at 37 ºC with shaking and growth was measured 
spectrophotometrically hourly. 
 
Anaerobic growth curves 
Media was degassed overnight in an anaerobic chamber to allow residual 
oxygen to diffuse out of the media. Overnight cultures of cells were first grown 
aerobically and were back diluted into anaerobic media to a concentration of 103 
CFUs/mL. Samples were removed from the chamber daily and plated by 10-fold serial 
dilutions to enumerate CFUs. 
 
Structure prediction 
The Phyre2 protein modeling web portal was used to generate a predicted model 
of L. monocytogenes 10403S GcpE (75).  
 
Sample Preparation for Mass Spectrometry 
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L. monocytogenes cultures were grown aerobically and 250 µL of overnight 
culture were backdiluted into 10 mL anaerobic media, then incubated anaerobically for 2 
days at 37 ºC. Cultures were removed from the anaerobic chamber and centrifuged at 
4,300 RCF for 15 mins at 4 ºC. After centrifugation, the supernatant was aspirated and 
cell pellets were snap frozen in liquid nitrogen. Bacteria were resuspended in 1 mL 
sterile PBS, transferred to a tared 1.5 mL microcentrifuge tube with PBS, and pelleted 
again at 16,000 RCF for 1 min. The supernatant was aspirated and then snap frozen in 
liquid nitrogen again. Samples were stored at -80 ºC until HMBPP extraction step. 
 
HMBPP Extraction from L. monocytogenes 
500 μL of ice-cold acetonitrile/methanol/water (2:2:1, v/v/v) containing 0.1% 
ammonium hydroxide was added to bacterial pellet. 2-3 beads (3 mm) were added to 
microcentrifuge tube and tubes were vortexed for 10 mins in a Tissuelyser-48 
(Shanghai Jingxin Industrial Development Co., Ltd). Lysates were centrifuged for 5 mins 
at 20,000 RCF in a microcentrifuge, and 450 μL of supernatant was transferred to a 
clean 1.5 mL microcentrifuge tube. The pellet was extracted with another 500 μL of 
extraction solvent as described above. The supernatants were combined, and the 
extract (approximately 900 µL) was evaporated under a stream of nitrogen gas at room 
temperature. The residue was dissolved in 100 μL of 10 mM ammonium acetate, 
adjusted to pH 9.0 with ammonium hydroxide, and 100 μL of chloroform was added to 
extract the hydrophobic compounds. The extract was then centrifuged for 5 mins at 
20,000 RCF to facilitate fast phase separation. 50 μL of the aqueous phase was 
transferred to a new 1.5 mL microcentrifuge tube then 50 μL acetonitrile was added, 
and samples were centrifuged for 5 mins at 20,000 RCF to remove any precipitates. 
The supernatant was then analyzed by liquid chromatography-triple quadrupole mass 
spectrometry (LC-MS/MS) as described below. 
 
HILIC Separation Conditions 
An ACQUITY UPLC BEH HILIC Column (1.7 μm, 100´2.1 mm; Waters) was 
used for separation. Solvent A contained 20 mM ammonium acetate adjusted to pH 9.4 
with LC–MS grade ammonium hydroxide. Solvent B contained 80% acetonitrile and 20 
mM ammonium acetate adjusted to pH 9.4 with LC–MS grade ammonium hydroxide. 
The solvent gradient profile is described as follows: 0-5 mins, 100% solvent B gradually 
changed to 84%; 5-10 mins, elution with 84% solvent B; 10-11 mins, 16% solvent A 
gradually changed to 40%; 11-15 min, column wash with 40% solvent A; 15-30 mins, 
column equilibration with 100% solvent B. Separation was performed at 40 °C with a 
flow rate of 200 μL min–1 and 10 μL was injected. 
 
MS Method and Data Processing 
A Thermo ScientificTM DionexTM UltiMateTM 3000 UHPLC system coupled with Q 
Exactive hybrid quadrupole-Orbitrap mass spectrometer, equipped with heated 
electrospray ion (HESI) source, was used for LC-MS measurements. For better 
specificity and sensitivity, full scan data were acquired at 70,000 resolving power 
(FWHM at m/z 200), and MS scan range was 75-400 m/z. High resolution accurate 
mass (HRAM) data was acquired in negative ion mode. Source conditions were as 
follows: the sheath gas flow rate was 35 arbitrary units, and auxiliary gas flow rate was 
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8 arbitrary units; the spray voltage was 3.5 kV, and the capillary temperature was 
400°C; the AGC target was 106.  
The Xcalibur platform was used for spectra visualization, qualitative and 
quantitative analysis. The peak area of EIC (Extracted Ion Chromatogram) was used for 
quantification. The m/z of standard HMBPP in negative mode was 260.9940, and the 
extract ion precision was 10 ppm. The concentration of HMBPP was calculated by an 
external standard and standard curves were linear over ranges of 0.02-1 ng/µL for 
HMBPP with r2 greater than 0.996. Samples were normalized by initial pellet mass. 
 
Intravenous infections 
Intravenous (IV) infections were adapted from previously reported methods 
(76,77). Briefly, 8-week-old female CD-1 (Charles River) mice were infected IV with 105 
CFUs in 200 µL of PBS, and organs were harvested 48 hrs post infection. When mice 
were infected with ∆hmgR mutants, the inoculum was increased to 106 CFUs and 
organs were harvested 24 hours post infection due to the growth defect of this strain.  
To measure organ CFUs, mice were euthanized and spleens, livers, and gallbladders 
were removed, homogenized in 5, 10, or 0.5 mL of 0.1% IGEPAL CA-630 (Sigma), 
respectively, and plated to enumerate bacteria. 
 
Oral infections 
Oral infections were adapted from previously reported methods (52,78,79). 
Briefly, 5 mg/mL of streptomycin sulfate was added to the drinking water of 8-week-old 
female CD-1 (Charles River) mice two days prior to infection. One day prior to infection, 
mice were transferred to clean cages and chow was removed to fast the mice overnight. 
Mice were fed a small piece of white bread inoculated with 107 CFUs of L. 
monocytogenes in 5 µL of PBS, and 3 µL of butter was overlaid on the bread. When 
mice were infected with ∆hmgR mutants, the inoculum was increased to 108 CFUs, due 
to the growth defect of this strain. After infection, mice were returned to cages with 
standard drinking water and chow. To measure infection burden, pellets were collected 
from each mouse, weighed, homogenized in 1 mL PBS, and plated by serial dilution to 
enumerate CFUs. Homogenates were plated on selective BHI agar supplemented with 
6 g/L lithium chloride, 6 g/L glycine, 50 mg/L nalidixic acid, and 200 mg/L streptomycin 
(80). Pellets were collected daily for the first five days post-infection, and every two days 
for the remainder of the experiment. These studies were carried out in strict accordance 
with the recommendations in the Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health. All protocols were reviewed and approved by the 
Animal Care and Use Committee at the University of California, Berkeley (AUP-2016-
05-8811). 
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Supplemental Figure 2.1. EGD-e ∆hmgR grows on BHI agar without mevalonate.  
Clockwise from top left: plate images of EGD-e cultured aerobically with mevalonate, 
aerobically without mevalonate, and anaerobically without mevalonate. 
 
Figure S1
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Supplemental Figure 2.2. Nonmevalonate pathway mutants do not have virulence 
defects.  
A. CFUs recovered from CD-1 mice two days after IV infection with 105 CFUs of 
indicated L. monocytogenes strains. B. CFUs recovered from mice five days after oral 
infection with indicated L. monocytogenes strains. C. CFUs recovered from additional 
mouse organs, five days after oral infection with indicated L. monocytogenes strains. 
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Supplemental Figure 2.3. Phylogenetic tree of gcpE genes from various L. 
monocytogenes laboratory strains and clinical isolates.  
Strains are colored by serotype. 
 
 
Supplemental Methods 
Phylogenetic tree of gcpE alleles 
 PCRs were performed on laboratory strains and human placental isolates to 
amplify gcpE from each strain. Gel extractions were performed using QIAprep 2.0 spin 
columns (Cat No. 27115), according to manufacturer’s instructions. Sequencing was 
performed using Sanger sequencing, and phylogenetic tree was constructed using 
Interactive Tree Of Life (iTOL) v4 (81).  
Figure S3
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Table 2.1: L. monocytogenes strains 
 
Strain Description Reference 
DP-L6253 10403S WT (82) 
DP-L6700 ∆hmgR This study 
DP-L6701 ∆hmgR + pPL2-hmgR This study 
DP-L197 EGD-e (82) 
DP-L6702 EGD-e ∆hmgR This study 
DP-L6703 FSL N1-017 (83) 
DP-L6704 FSL N1-017 ∆hmgR This study 
DP-L6705 HPB2262 (Aureli 1997) (39) 
DP-L6706 HPB2262 ∆hmgR This study 
DP-L6707 ∆hmgR + pPL2-ispD (10403S) This study 
DP-L6708 ∆hmgR + pPL2-ispD (FSL N1-017) This study 
DP-L6709 ∆hmgR + pPL2-ispD (HPB2262) This study 
DP-L6710 ∆hmgR + pPL2-gcpE (10403S) This study 
DP-L6711 ∆hmgR + pPL2-gcpE (FSL N1-017) This study 
DP-L6712 ∆hmgR + pPL2-gcpE (HPB2262) This study 
DP-L6713 ∆hmgR + pPL2-lytB (10403S) This study 
DP-L6714 ∆hmgR + pPL2-lytB (FSL N1-017) This study 
DP-L6715 ∆hmgR + pPL2-lytB (HPB2262) This study 
DP-L6716 ∆hmgR∆gcpE This study 
DP-L6717 ∆hmgR∆gcpE + pPL2-gcpE (P10403S 10403S) This study 
DP-L6718 ∆hmgR∆gcpE + pPL2-gcpE (P10403S FSL N1-017) This study 
DP-L6719 ∆hmgR∆gcpE + pPL2-gcpE (P10403S HPB2262) This study 
DP-L6720 ∆hmgR∆gcpE + pPL2-gcpE (10403S1-250/FSL N1-017251-369) This study 
DP-L6721 ∆hmgR∆gcpE + pPL2-gcpEI343V/D344E This study 
DP-L6722 ∆hmgR∆gcpE + pPL2-gcpEF357Y/V359E This study 
DP-L6723 ∆hmgR∆gcpE + pPL2-gcpEK291T/E293K/V294A This study 
DP-L6724 ∆hmgR∆gcpE + pPL2-gcpEK291T This study 
DP-L6725 ∆hmgR∆gcpE + pPL2-gcpEV294A This study 
DP-L6726 ∆hmgRgcpEK291T/E293K/V294A This study 
DP-L2209 hly::Tn917 (51) 
DP-L6727 gcpEK291T/E293K/V294A This study 
DP-L6728 gcpEK291T/E293K/V294A hly::Tn917 This study 
DP-L6729 ∆gcpE This study 
DP-L6730 ∆gcpE hly::Tn917 This study 
DP-L6731 ∆lytB This study 
DP-L6732 ∆lytB hly::Tn917 This study 
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Table 2.2: E. coli strains 
 
Strain Plasmid or genotype Reference 
XL1-Blue Cloning; recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́proAB lacIq 
Z∆M15 Tn10 (Tetr)]  
Stratagene 
TOP10 Cloning; F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lacX74 recA1 
araD139 Δ( araleu)7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen 
SM10 Conjugation; thi-1 thr-1 leuB6 tonA21 lacY1 supE44 recA λ- integrated [RP4-
2-Tcr::Mu] aphA+ (Kmr) Tra+ 
(84)  
DP-E6324 pKSV7-oriT (85)  
DP-E6733 pKSV7-∆hmgR (10403S/FSL N1-017) This study 
DP-E6734 pKSV7-∆hmgR (EGD-e) This study 
DP-E6735 pKSV7-∆hmgR (HPB2262) This study 
DP-E6736 pKSV7-∆gcpE This study 
DP-E6737 pKSV7-∆lytB This study 
DP-E6738 pKSV7-gcpEK291T/E293K/V294A This study 
DP-E6333 pPL2t (86)  
DP-E6739 pPL2-ispD (10403S) This study 
DP-E6740 pPL2-ispD (FSL N1-017) This study 
DP-E6741 pPL2-ispD (HPB2262) This study 
DP-E6742 pPL2-gcpE (10403S) This study 
DP-E6743 pPL2-gcpE (FSL N1-017) This study 
DP-E6744 pPL2-gcpE (HPB2262) This study 
DP-E6745 pPL2-lytB (10403S) This study 
DP-E6746 pPL2-lytB (FSL N1-017) This study 
DP-E6747 pPL2-lytB (HPB2262) This study 
DP-E6748 pPL2-gcpE (P10403S FSL N1-017) This study 
DP-E6749 pPL2-gcpE (P10403S HPB2262) This study 
DP-E6750 pPL2-gcpE (10403S1-250/FSL N1-017251-369) This study 
DP-E6751 pPL2-gcpEI343V/D344E This study 
DP-E6752 pPL2-gcpEF357Y/V359E This study 
DP-E6753 pPL2-gcpEK291T/E293K/V294A This study 
DP-E6754 pPL2-gcpEK291T This study 
DP-E6755 pPL2-gcpEV294A This study 
DP-E6756 pPL2-hmgR This study 
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Chapter 3 
 
Activation of the two-component system LisRK increases L. monocytogenes 
growth using the nonmevalonate pathway of isoprenoid biosynthesis 
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3.1 Summary of results 
 The nonmevalonate pathway of isoprenoid precursor biosynthesis was recently 
found to be sufficient for L. monocytogenes growth in anaerobic conditions. We showed 
that lineage II strains and lineage I L. monocytogenes strains encoded different alleles 
of the nonmevalonate pathway enzyme GcpE, which led to distinct differences in 
anaerobic growth rates between strains. This observation demonstrated that 
nonmevalonate pathway growth could be altered with mutations in the pathway itself, 
but left the question of whether any other proteins also helped regulate the 
nonmevalonate pathway. We anaerobically passaged a mutant in the nonmevalonate 
pathway, ∆hmgR, and used whole genome sequencing to identify suppressor mutations 
that allowed this mutant to grow faster using the nonmevalonate pathway. Three unique 
point mutations were identified in the histidine kinase LisK, which is part of the two-
component regulatory system LisRK. A frameshift mutation was also identified in the 
protease ClpC, but was not studied further. Deleting lisK from ∆hmgR caused bacteria 
to lyse in the absence of mevalonate, suggesting that the suppressor mutations 
activated or altered LisRK signaling. However, we were unable to identify any genes 
whose expression obviously changed in different LisRK mutant strains. This study 
suggests that the nonmevalonate pathway can be activated in response to 
environmental signals, but further studies are needed to better define the LisRK regulon 
in strain 10403S.  
 
3.2 Introduction 
 Isoprenoid precursor biosynthesis is an essential process in all cells. Isoprenoid 
precursor molecules, isopentenyl pyrophosphate (IPP) and dimethyl-allyl pyrophosphate 
(DMAPP) can be produced by two unique biosynthetic pathways in bacteria, called the 
mevalonate pathway and the nonmevalonate pathway (7). Most bacteria have one 
pathway or the other, but Listeria monocytogenes is unique in that it has genes for both 
pathways (9,10). Work from previous authors report that the mevalonate pathway is 
essential for L. monocytogenes growth, but recently we demonstrated that the 
nonmevalonate pathway was sufficient for anaerobic growth, even if the rate limiting 
gene of the mevalonate pathway was deleted. 
 Furthermore, we observed that different strains of (39) L. monocytogenes had 
substantially different growth phenotypes when hmgR was deleted (∆hmgR) and the 
bacteria were cultured anaerobically. One environmental and one clinical isolate, FSL 
N1-017 (70) and HPB2262 Aureli 1997 (39), grew significantly faster on the 
nonmevalonate pathway than two commonly used laboratory strains, 10403S and EGD-
e. Three amino acid changes in the nonmevalonate pathway enzyme GcpE were 
sufficient to increase 10403S growth rates to the same rate as the lineage I strains. All 
three changes, K291T, E293K, and V294A, needed to be present to alter L. 
monocytogenes growth, and any single mutation did not alter growth rates. 
 We were curious whether we could better understand the regulatory network 
controlling the nonmevalonate pathway, by identifying other suppressor mutations that 
also increased the growth rate of 10403S ∆hmgR. Suppressor mutations were identified 
by utilizing the severe anaerobic growth defect of 10403S ∆hmgR, which made it 
possible to isolate mutants that grew faster anaerobically. Specific mutations were 
identified using whole genome sequencing and were further characterized with 
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molecular genetics. The results of this study demonstrate that several unique point 
mutations in the histidine kinase LisK significantly increased ∆hmgR anaerobic growth 
rates. The precise mechanism of these mutations was not identified, but the data 
suggest that these mutations activate or increase signaling in the two-component 
system LisRK, rather than disrupting signaling. 
 
3.3 Results 
 
3.3.1 Identification of suppressor mutations that alter L. monocytogenes growth 
using the nonmevalonate pathway 
 Fast growing suppressor mutants were isolated by sequentially passaging 
∆hmgR anaerobically in BHI broth. We reasoned that any ∆hmgR mutants that grew 
faster anaerobically would have a competitive advantage in broth culture, which would 
allow the fast-growing suppressor mutants to outcompete parental ∆hmgR bacteria over 
the course of several passages. Six cultures were started from unique colonies on 
plates and each was grown anaerobically for five passages. No changes in growth were 
observed for the first two passages and each culture required four to five days to grow 
to turbidity (OD » 1.0). Growth rate increased from the third passage onward, as each 
passage required two days to reach stationary phase anaerobically. Aliquots from the 
fifth passage were frozen, thawed to confirm that the fast growth was maintained, 
before genomic DNA was prepared and sent for whole genome sequencing. 
 Suppressor mutations were mapped to five different genes (Table 3.1). Mutations 
in identified in culture 2 were not fully penetrant, likely as a result of the method used to 
isolate suppressor mutations. Five out of the six cultures had mutations in the histidine 
kinase LisK and one of the cultures also had another mutation in the response regulator 
LisR. As a result, we focused on these genes for further characterization. A transposon 
in the gene lmo1389 (lmo1389::himar1) was used to transduce the suppressor 
mutations from cultures 1, 3, and 4, into a clean ∆hmgR background, and Sanger 
sequencing was used to confirm that the LisK mutations had been transduced. These 
rederived LisK* mutants (∆hmgR lisK* 1, ∆hmgR lisK* 3, and ∆hmgR lisK* 4) were the 
strains used for all subsequent analyses. Anaerobic growth curves confirmed that the 
resulting strains had a similar fast growing phenotype in broth cultures (Fig. 3.1A). 
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Table 3.1: Suppressor mutations identified from ∆hmgR anaerobic cultures 
Culture 
lisK 
(lmo1378) 
lisR 
(lmo1377) 
multidrug ABC 
transporter ATP-
binding protein 
(lmo1505) 
ATP-dependent Clp 
protease ATP-binding 
subunit ClpC 
(lmo0232) 
glycosidase 
(lmo2444) 
1  
Glu276Lys 
    
2 Val84Gly 
Arg172Trp 
1302A>G 
435C>T  
(-243 of lisR) 
  Ala46fs 
3 Phe260Val     
4 Ile36Val     
5 Arg176Leu   Asn25fs  
6   Asp24fs   
 
Table 3.1: Suppressor mutations identified in ∆hmgR cultures.  
DNA and amino acid mutations identified by Illumina HiSeq whole genome sequencing 
of fast-growing ∆hmgR suppressor mutants. Amino acid mutations are listed, and base 
pairs are indicated if a change resulted in a silent mutation at the amino acid level. 
Frame-shift mutations are indicated by “fs.” 
 
 
3.3.2 Deleting the histidine kinase LisK severely impairs ∆hmgR growth 
aerobically and anaerobically 
 LisR and LisK form a bacterial signaling network called a two-component system. 
Two-component systems (TCSs) are multi-protein signaling networks that help bacteria 
sense extracellular environmental changes and transcriptionally alter genetic programs 
that help them survive in that new environment (87). At their simplest, TCSs have a 
transmembrane histidine kinase that, in response to its activating signal, forms a 
homodimer that autophosphorylates a histidine residue located in the kinase domain of 
the protein. This activated histidine kinase then interacts with its cognate response 
regulator and transfers the activated phosphate group to an aspartate residue on the 
response regulator. The phosphorylated response regulator can then act as either a 
transcriptional activator or repressor for the genes in its regulon. 
 LisRK is one of sixteen known TCSs in L. monocytogenes and has been 
implicated in tolerance of osmotic stress and cell membrane stress (88–91). However, 
neither its activating signal nor its DNA binding sequence motif have been identified. To 
examine the effect of the suppressor mutations on LisK signaling, lisK was deleted from 
∆hmgR (∆hmgR∆lisK). Unexpectedly, ∆hmgR∆lisK had a significantly different growth 
phenotype than ∆hmgR when grown aerobically in BHI broth (Fig. 3.1B). In high 
mevalonate concentrations, ∆hmgR had no growth defect relative to WT, but 
∆hmgR∆lisK took slightly longer to reach stationary phase. Furthermore, ∆hmgR grew 
slightly without mevalonate, eventually reaching a stationary phase after approximately 
four hours of growth. In contrast, ∆hmgR∆lisK growth stopped at approximately the 
same time, but the OD decreased over the time course until it was undetectable 24 
hours post inoculation. Live microscopy was used to observe bacterial growth as 
∆hmgR and ∆hmgR∆lisK reached stationary phase (Fig. 3.2). Upon inoculation, ∆hmgR 
divided several times, but stopped dividing after approximately four hours. In contrast, 
 32 
∆hmgR∆lisK bacteria continued growing and formed very elongated cells shapes. As 
time passed, bacteria eventually disappeared from the field of view, which suggested 
that bacteria were lysing. 
 
 
 
Figure 3.1. Suppressor mutations in lisK increase anaerobic growth of ∆hmgR.  
A. Anaerobic BHI growth curve of ∆hmgR and ∆hmgR suppressors with lisK mutations. 
B. Aerobic BHI growth curve of WT, ∆hmgR, and ∆hmgR∆lisK. ∆hmgR and ∆hmgR∆lisK 
were grown in BHI with (+) or without (-) 2.5 mM mevalonate. 
 
 
3.3.3 Mutations in LisRK do not impact growth or virulence 
 Due to the significant in vitro growth phenotypes observed in ∆hmgR∆lisK, we 
were curious whether mutating the LisRK TCS alone impacted growth or pathogenesis 
of 10403S. Neither a lisK mutant (∆lisK) or lisR mutant (∆lisR) had a growth defect in 
bone marrow derived macrophages (Fig. 3.3A), but ∆lisK infection of macrophages 
caused slightly higher levels of host cell death in a lactate dehydrogenase assay (Fig. 
3.3B). After a 48 hour intravenous infection, there was no significant change in virulence 
(Fig. 3.3C). This is in contrast to ∆hmgR∆lisK infections, because recoverable CFUs in 
macrophases rapidly decreased to below the limit of detection by the final eight-hour 
time point (Fig. 3.3D). 
 These observations suggested that the suppressor mutations in LisK were not 
disrupting or blocking LisRK signaling, but were instead constitutively activating 
signaling. As a result, we further characterized the ∆hmgR lisK* mutants in the same 
assays to determine whether the suppressor mutations had different impacts on 
bacterial than a lisK deletion. All three ∆hmgR lisK* mutants grew significantly more in 
bone marrow derived macrophages relative to the original ∆hmgR strain (Fig. 3.3E). 
They also caused significantly less host cell death than ∆hmgR, which is likely the 
reason more CFUs were recovered eight hours post infection. These data were 
consistent with the hypothesis that LisK suppressor mutations were activating rather 
than inhibitory, so we sought to directly link LisRK signaling and the nonmevalonate 
pathway. 
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Figure 3.2. Live microscopy of ∆hmgR and ∆hmgR∆lisK.  
Two representative fields of view from ∆hmgR and ∆hmgR∆lisK growth on a BHI agar 
pad without mevalonate. ∆hmgR divides several times, but stops growing at 
approximately 4 hours post inoculation. Individual ∆hmgR∆lisK cells begin disappearing 
from the field of view at approximately 4 hours post inoculation. 
∆hmgR∆lisK∆hmgRTime
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Figure 3.3. LisRK mutations dramatically impair growth in combination with 
∆hmgR, but do not impact virulence on their own.  
A. Bone marrow-derived macrophage growth curve of LisRK mutants. Neither ∆lisK, 
∆lisR, or ∆lisRK have virulence defects in bone marrow-derived macrophages. B. 
Lactate dehydrogenase release assay of ∆hmgR lisK* strains. ∆hmgR lisK* mutants 
induce significantly less cell death than ∆hmgR, while ∆hmgR ∆lisK induces significantly 
more cell death. C. CFUs recovered from indicated organs one day after IV infection 
with WT or ∆lisK L. monocytogenes. ∆lisK does not have a significant growth defect 
compared to WT. D. Bone marrow-derived macrophage growth curve of ∆hmgR ∆lisK 
mutant. ∆hmgR ∆lisK has a severe growth defect and does not survive in cells over the 
course of an eight hour growth curve. E. Bone marrow-derived macrophage growth 
curve of WT, ∆hmgR, and three ∆hmgR lisK* suppressor mutants. 
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3.3.4 GcpE and LytB expression levels do not change anaerobically 
 Based on our prior work with the lineage I strains FSL N1-017 and HPB2262 we 
were curious whether strain-specific differences existed that could contribute to growth 
on the nonmevalonate pathway. To examine whether regulatory factors in each strain 
could alter growth, both gcpE and lytB were deleted from FSL N1-017 (FSL ∆gcpE and 
FSL ∆lytB), HPB2262 (HPB ∆gcpE and HPB ∆lytB), and EGD-e (EGD-e ∆gcpE and 
EGD-e ∆lytB). Next, 6xHis-tagged copies of 10403S gcpE and 10403S lytB were 
complemented into their respective deletion strains, so that each strain expressed gcpE 
or lytB from 10403S. These genes were chosen because they are the rate-limiting steps 
in the nonmevalonate pathway, and we previously observed that minor changes to the 
GcpE coding sequence significantly impacted L. monocytogenes anaerobic growth 
using the nonmevalonate pathway. We then asked whether protein levels of GcpE or 
LytB changed in any of these strains, under aerobic or anaerobic conditions. No 
changes in either GcpE (Fig. 3.4A) or LytB (Fig. 3.4B) were detected in any of the 
strains by Western Blot. The loading control varied significantly in the first blot, but when 
it was repeated with select strains, we observed similar results (Fig. 3.4C, 3.4D).  
 
 
 
Figure 3.4. Western blot for GcpE and LytB in aerobic and anaerobic conditions   
A. Western blot for 6xHis-GcpE in indicated L. monocytogenes strains, when cultured 
aerobically and anaerobically. B. Western blot for 6xHis-LytB in indicated L. 
monocytogenes strains, when cultured aerobically and anaerobically. C. Replicate of 
previous Western blots using 10403S strains. D. Replicate of previous Western blots 
using EGD-e strains. 
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3.3.5 Genes in the nonmevalonate pathway are not part of the LisRK regulon  
 Several studies have attempted to define the LisRK regulon in L. 
monocytogenes. One study showed that deleting lisK increased sensitivity to sodium 
chloride (89), while another used the more generalized approach of comparing 
microarray data between WT and ∆lisR in response to cefuroxime, a ß-lactam antibiotic 
that targets cell wall synthesis (90). Both studies used the strain LO28, which is a 
serotype 1/2c strain, in comparison to the more-commonly used strains 10403S and 
EGD-e, both of which are serotype 1/2a. The second study showed that the gene 
encoding undecaprenyl diphosphate synthase, lmo1315, is upregulated in response to 
cefuroxime in WT, but not in ∆lisR (90). UPP synthase is downstream of both isoprenoid 
precursor pathways, but is an essential step in the undecaprenol biosynthesis pathway. 
The lmo1315 operon also contains dxr, which is the second committed step of the 
nonmevalonate pathway. We hypothesized that the LisK* suppressor mutations could 
constitutively upregulate this operon, thereby increasing anaerobic growth using the 
nonmevalonate pathway. 
 Quantitative real-time PCR (qRT-PCR) was performed on bacteria to examine 
whether expression levels of any putative LisRK-regulated genes changed with oxygen 
levels. We used qoxA (lmo0013) as a positive control, because it is known to be 
significantly downregulated anaerobically in L. monocytogenes. Anaerobically, qoxA 
mRNA levels decreased almost 5-fold in all strains (Fig. 3.5A), relative to aerobic 
conditions. dxr expression was measured in the same samples, but there were no 
obvious trends in dxr expression between ∆lisRK and lisK* mutants, either with or 
without oxygen (Fig. 3.5B). As a result, other reportedly LisRK-regulated genes were 
examined.  
 Lmo0292 is an HtrA-like protein, a class of heat shock proteins necessary for 
bacterial survival at high temperatures. Lmo0292 was found to be positively regulated 
by LisRK, because lmo0292 RNA levels at stationary phase decreased significantly 
when lisK was deleted from EGD-e (92). In 10403S ∆lisRK we observed that lmo0292 
expression increased both aerobically and anaerobically relative to WT (Fig. 3.5C), and 
LisK* mutants also had increased RNA levels. Since similar results were observed in 
both ∆lisRK and LisK* strains, it did not help elucidate the mechanism by which the 
suppressor mutations altered ∆hmgR anaerobic growth. 
 LisRK is reported to regulate a family of sRNAs, LhrC1-5, in the strain LO28 (93). 
They found that stress activates LisR, which upregulates LhrC1-5. These in turn 
suppress several genes, including a heme oxygenase-like protein lmo0484. Even 
though their data showed only a modest increase in lmo0484 expression in a ∆lhrC1-5 
strain one hour after cefuroxime exposure, we still chose to measure lmo0484 
expression by qPCR in our LisK* mutants. We observed no significant changes in 
lmo0484 expression level between mutants, including ∆lisR, ∆lisRK, and the LisK* 
mutants (Fig. 3.5D). 
 One confounding factor of this study was potential variation between anaerobic 
sample prep, and a failure to confirm that previous results, such as LisRK activation in 
response to cefuroxime stress, repeated in 10403S. Future studies would benefit from a 
more “omics-based” approach, using a combination of LisRK knockouts and suppressor 
mutants to define the LisRK regulon and its relationship with the nonmevalonate 
pathway. 
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Figure 3.5. qRT-PCR of potential LisRK-regulated genes in aerobic and anaerobic 
conditions.  
A. Relative expression levels of qoxA in L. monocytogenes strains grown aerobically 
and anaerobically. B. Relative expression levels of dxr in L. monocytogenes strains 
grown aerobically and anaerobically. C. Relative expression levels of lmo0292 in L. 
monocytogenes strains grown aerobically and anaerobically. D. Relative expression 
levels of lmo0484 in L. monocytogenes strains grown aerobically. 
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3.4 Discussion 
 Previous work demonstrated that genetic differences in the nonmevalonate 
pathway enzyme GcpE significantly increased 10403S ∆hmgR growth anaerobically. In 
this work, we examined whether suppressor mutations in 10403S ∆hmgR could also 
increase anaerobic growth rates, to gain a better understanding of how the 
nonmevalonate pathway is regulated in L. monocytogenes. We isolated mutations in 
∆hmgR that increased growth using the nonmevalonate pathway by sequentially 
passaging cultures anaerobically and performing whole genome sequencing to identify 
mutations.  
Multiple mutations in the two-component system LisRK arose in fast-growing 
strains. All of the mutations caused point mutations rather than frameshift mutations, 
which was curious because it is statistically far more likely for a frameshift mutation to 
occur. This suggested that the mutations maintained LisRK signaling instead of causing 
a loss-of-function mutation. Indeed, we observed that ∆hmgR∆lisK lysed in broth without 
mevalonate, which supported the hypothesis that our suppressor mutations altered, 
rather than disrupted, LisRK signaling. Work from other authors had identified one gene 
involved with isoprenoid biosynthesis, lmo1315, as being transcriptionally regulated by 
LisR in the L. monocytogenes strain LO28. However, in 10403S neither lmo1315 nor 
dxr expression levels changed in the presence or absence of LisR or LisK, when 
comparing aerobic or anaerobic conditions. These observations do not exclude the 
possibility that the operon is upregulated in response to cefuroxime stress, but this 
condition was not tested. 
Several questions will likely need to be answered in order to gain a better 
understanding of the relationship between LisRK and the nonmevalonate pathway. A 
putative LisRK DNA binding sequence was recently identified, and it would be 
interesting to perform a more complete bioinformatics analysis to define the LisRK 
regulon (94). Additionally, identifying the specific activating signal may reveal conditions 
in which the nonmevalonate pathway is activated, and provide more insight into why L. 
monocytogenes has two isoprenoid pathways. To this end, it would be useful to 
translationally fuse a LisRK regulated 5’ UTR to a reporter gene such as ß-
galactosidase or ß-glucaronidase, which would be a means of easily screening 
conditions in which the two-component system is activated. 
Ultimately, we failed to clearly define a connection between the nonmevalonate 
pathway and LisRK, but there are several interesting possibilities that may warrant 
further investigation. LisR regulates a set of small regulatory RNAs, lhrC1-5, in a heme-
dependent manner, with lhrC1-5 downregulating their target genes in response to heme 
stress (93). Among the lhrC1-5 regulated genes is lmo0484, a heme-monooxygenase 
that helps maintain iron homeostasis. Even though no consistent changes in lmo0484 
mRNA levels were observed, two enzymes in the nonmevalonate pathway, GcpE and 
LytB, contain iron-sulfur clusters and have been shown to be the only essential iron-
sulfur cluster containing enzymes in Escherichia coli and Bacillus subtilis (59,60). Thus, 
it may be worth examining whether there is any connection between LisRK activation, 
lhrC1-5 regulation, and iron-sulfur cluster biosynthesis in L. monocytogenes. 
 One of the significant challenges with this study was simply that two-component 
systems are not well characterized outside of a few model organisms. Additionally, our 
previous work demonstrated that there are significant strain-specific differences in 
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nonmevalonate pathway genes that can alter the pathway’s function. All previous LisRK 
studies in L. monocytogenes used EGD-e or LO28, which may have impacted our ability 
to replicate previously published results. Furthermore, those studies varied in whether 
they examined histidine kinase deletions, response regulator deletions, or deletions that 
remove the entire two component system. As a result, it is difficult to rule out the 
possibility that cross-talk between unrelated two-component systems with LisR or LisK 
was responsible for the inconsistencies between studies (87). 
One entirely unaddressed question is how the frameshift mutation identified in 
ClpC impacts anaerobic growth on the nonmevalonate pathway. ClpC is the protease 
responsible for degrading MurA, a key peptidoglycan hydrolase involved with 
peptidoglycan biosynthesis in B. subtilis and L. monocytogenes (95–97). ClpC 
disruption leads to MurA accumulation, which can in turn increase the production of 
UDP-N-acetylglucosamine (UDP-GlcNAc) and stimulate cell wall biosynthesis. 
Curiously, a ClpC transposon (DP-L5647) was previously identified in a screen for 
hyperhemolytic mutants in 10403S, which may also would be useful for further 
examining this hypothesis. Presently, we believe that the slow growth observed in 
10403S is due to a metabolic bottleneck within the nonmevalonate pathway, and 
mutations in GcpE relieve this bottleneck. Further analysis of a ClpC mutant and UDP-
GlcNAc accumulation may reveal another metabolic bottleneck that influences ∆hmgR 
growth, outside of the nonmevalonate pathway enzymes. 
Our previous study found that mutations in GcpE, which increased the growth 
rate of ∆hmgR, did not significantly increase HMBPP production. The suppressor 
mutations identified in this study may provide an alternative means of manipulating 
HMBPP production, which may prove useful as we gain a better understanding of 
Vg9Vd2 T-cells. These suppressor mutations in LisRK also suggest that the 
nonmevalonate pathway may be activated in response to particular environmental cues, 
so it would be exciting to search for the exact activating stimulus. 
 
 
3.5 Materials and Methods 
 
Construction of L. monocytogenes strains 
The L. monocytogenes strains used in this study are all derived from wild-type 
10403S (DP-L6253) unless otherwise noted and are listed in Table 3.2. Gene deletions 
were generated by allelic exchange using the plasmid pKSV7 (74). All L. 
monocytogenes strains were grown in brain heart infusion (BHI) broth and media was 
supplemented with 1 mM mevalonate as needed to support the growth of auxotrophic 
∆hmgR strains. Mevalonate was produced by hydrolyzing DL-mevalonolactone (Sigma-
Aldrich CAS Number 674-26-0) with 1 N NaOH at 37 ºC for 1 hour, according to 
previously reported methods (35). Strains were cultured anaerobically using a BD 
GasPak EZ anaerobic pouch system (Cat no. 260683). 
E. coli strains used in this study are listed in Table 3.3. For vector construction, 
plasmids were introduced into TOP10 E. coli (Invitrogen) or XL1 Blue E. coli 
(Stratagene). Plasmids were then transformed into SM10 E. coli and conjugated into L. 
monocytogenes. PCR was performed with KAPA HiFi DNA polymerase (Kapa 
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Biosystems). Positive clones were identified by performing colony PCRs using 
SapphireAmp Fast PCR Master Mix (Takara Bio) and verified by Sanger sequencing. 
 
Generation of ∆hmgR suppressor mutations 
Methods for generating suppressor mutations were adapted from previously 
published protocols (86). Six independent ∆hmgR cultures were incubated anaerobically 
without mevalonate for five days until they reached stationary phase. Cultures were 
then backdiluted in fresh BHI and grown anaerobically again until they reached 
stationary phase. This process was repeated four times in total, at which point the 
cultures grew to stationary phase within two days. Each culture was then frozen down, 
thawed, and anaerobic growth phenotype was confirmed before genomic DNA was 
prepared. 
 
Whole Genome Sequencing 
Genomic DNA was prepared from a 5 mL overnight culture of bacteria using a 
MasterPure Gram Positive DNA Purifiation Kit (Epicentre, MGP04100) according to 
manufacturer’s instructions. DNA was submitted for library preparation and was 
sequenced using single-read 50 Illumina sequencing at the Vincent J. Coates Genomics 
Sequencing Laboratory at UC Berkeley, supported by NIH S10 OD018174 
Instrumentation Grant. Data was assembled and aligned to the 10403S reference 
genome (GenBank: GCA_000168695.2) and SNP/InDel/structural variation of strains 
was determined using CLC Genomics Workbench (QIAGEN Bioinformatics). 
 
Phage transduction  
Generalized transduction was performed as previously described (98) using the 
U153 phage (99). Briefly, phage were propagated in L. monocytogenes MACK (DP-
L861) at 30 ºC. To generate a transducing lysate, approximately 109 CFUs of donor 
strain was combined with ~107 plaque forming units (PFUs) of U153 and immobilized in 
0.7% LB agar with 10 mM MgSO4 and 10 mM CaCl2 overnight at 30 ºC. Recovered 
phage could be used for generalized transduction by lysogenizing 108 CFUs of recipient 
L. monocytogenes with ~107 PFU of transducing lysate in LB broth with 10 mM MgSO4 
and 10 mM CaCl2, incubating for 30 mins at room temperature, and selecting for 
erythromycin on selective BHI agar at 37 ºC. 
 
Aerobic growth curves 
Strains were grown overnight at 37 ºC in filter-sterilized BHI and were 
supplemented with 500 µM mevalonate as necessary. Cells were washed with PBS and 
diluted in 20 mL fresh BHI. Cells were cultured at 37 ºC with shaking and growth was 
measured spectrophotometrically by optical density at a wavelength of 600 nm (OD600). 
 
Anaerobic growth curves 
Media was degassed overnight anaerobically to allow residual oxygen to diffuse 
out of the media. Overnight cultures of cells were first grown aerobically and were back 
diluted into anaerobic media to a concentration of 103 CFUs/mL. Samples were 
removed from the glovebox daily and plated by 10-fold serial dilutions to enumerate 
CFUs. 
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Intravenous infections 
Intravenous (IV) infections were adapted from previously reported methods 
(76,77). Briefly, 8-week-old female CD-1 (Charles River) mice were infected IV with 105 
CFUs in 200 µL of PBS, and organs were harvested 48 hrs post infection. To collect 
organs, mice were euthanized and spleens and livers were removed, homogenized in 5 
or 10 mL of 0.1% IGEPAL CA-630 (Sigma), respectively, and plated to enumerate 
bacterial burdens. 
 
Lactate Dehydrogenase Assay 
L. monocytogenes strains were grown overnight at 30 ºC in BHI without shaking. 
Bone marrow-derived macrophages were plated at 5 x 105 cells per well in a 24-well 
plate, in standard media supplemented with PAM3CSK. Cells were infected with a 
multiplicity of infection (MOI) of 2 and lactate dehydrogenase release assay was 
performed according to previously published methods (100). 
 
Intracellular Macrophage Growth Curve 
Bone marrow-derived macrophages were harvested as described previously 
(101). Briefly, 3 x 106 cells were plated in 60 mm non-TC treated petri dishes. Cells 
were infected with a multiplicity of infection (MOI) of 0.1 and growth curves were 
performed as described previously (102).  
 
Immunoblots for GcpE and LytB 
All immunoblotting was performed as previously described (103). Briefly, 
overnight cultures were diluted 1:10 into aerobic or anaerobic BHI, incubated for five 
hours at 37 °C, then bacteria were pelleted by centrifugation. Bacterial pellet was 
washed with 1 mL of PBS, then pelleted for 1 min at 13,000 RPM and supernatant was 
removed. The pellet was resuspended in 100 µL of 0.1% IGEPAL CA-630 (Sigma) and 
0.1 mM phenylmethylsulfonyl fluoride (PMSF), then 0.1 mm silica/zirconium beads were 
used to bead beat bacteria for 15 minutes. Bacterial lysates were centrifuged for 15 
mins at 13,000 RPM, then 90 µL of supernatant was transferred to a new tube and 30 
µL of 4x LDS Buffer (Invitrogen) containing 5% ß-mercaptoethanol was added. Samples 
were boiled for 20 minutes, and proteins were separated by SDS-PAGE.  
Primary antibody against the 6x-His tag was used at a dilution of 1:2,000 and a 
mouse monoclonal antibody against P60 (Adipogen) was used at a dilution of 1:5,000. 
P60 is a constitutively expressed bacterial protein used as a loading control (104). Goat 
a-mouse secondary antibody was used at a dilution of 1:5,000 and donkey a-rabbit 
antibody was used at a dilution of 1:10,000. All immunoblots were visualized and 
quantified using Odyssey Imager, according to the manufacturer’s instructions.  
 
Quantitative Real-time PCR (qPCR) of Bacterial Transcripts 
Overnight cultures of bacteria were backdiluted to OD600=0.01 into 5 mL BHI and 
grown in indicated conditions until they reached an OD600=1.0. An equal volume of 
RNAprotect Bacteria Reagent (Qiagen) was added to the culture to stop growth, and 
bacteria were harvested by centrifugation and flash frozen in liquid nitrogen prior to 
RNA extraction. Bacteria were lysed in phenol:chloroform containing 1% SDS by 
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vortexing with 0.1 mm silica/zirconium beads (BioSpec Products Inc.). Nucleic acids 
were precipitated from the aqueous fraction overnight at −80 °C in ethanol containing 
150 mM sodium acetate (pH 5.2). Precipitated nucleic acids were washed with ethanol 
and treated with TURBO DNase per manufacturer’s instructions (Life Technologies 
Corporation). RNA was again precipitated overnight and then washed in ethanol. RT–
PCR was performed with iScript Reverse Transcriptase (Bio-Rad) and quantitative PCR 
(qPCR) of resulting cDNA was performed with KAPA SYBR Fast using the 
manufacturer’s recommended cycling parameters (Kapa Biosystems). For each gene, 
two pairs of primers were designed using Primer3Plus, but only one primer pair was 
used, based on their melting curves. Primers for qPCR are listed in Table 3.4. 
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Table 3.2: L. monocytogenes strains 
 
Strain Description Reference 
DP-L6253 10403S WT (82) 
DP-L6700 ∆hmgR (Lee, ED et al. 2019) 
DP-L6729 ∆gcpE (Lee, ED et al. 2019) 
DP-L6731 ∆lytB (Lee, ED et al. 2019) 
DP-L6770 EGD-e ∆gcpE (Lee, ED et al. 2019) 
DP-L6771 EGD-e ∆lytB (Lee, ED et al. 2019) 
DP-L6772 FSL N1-017 ∆gcpE (Lee, ED et al. 2019) 
DP-L6773 FSL N1-017 ∆lytB (Lee, ED et al. 2019) 
DP-L6774 HPB2262 ∆gcpE (Lee, ED et al. 2019) 
DP-L6775 HPB2262 ∆lytB (Lee, ED et al. 2019) 
DP-L6776 ∆hmgR ∆lisK This study 
DP-L6777 ∆hmgR ∆lisR  This study 
DP-L6778 ∆lisK  This study 
DP-L6779 ∆lisR  This study 
DP-L6780 ∆lisRK  This study 
DP-L6781 ∆hmgR lisK*1 lmo1389::himar1  This study 
DP-L6782 ∆hmgR lisK*3 lmo1389::himar1  This study 
DP-L6783 ∆hmgR lisK*4 lmo1389::himar1  This study 
DP-L6784 ∆hmgR (Suppressor #1)  This study 
DP-L6785 ∆hmgR (Suppressor #2)  This study 
DP-L6786 ∆hmgR (Suppressor #3)  This study 
DP-L6787 ∆hmgR (Suppressor #4)  This study 
DP-L6788 ∆hmgR (Suppressor #5)  This study 
DP-L6789 ∆hmgR (Suppressor #6)  This study 
DP-L6790 ∆hmgR clpC::himar1  This study 
DP-L6791 ∆gcpE + pPL2-gcpE-6xHis (10403S) This study 
DP-L6792 ∆lytB + pPL2-lytB-6xHis (10403S) This study 
DP-L6793 FSL N1-017 ∆gcpE + pPL2-gcpE-6xHis (10403S) This study 
DP-L6794 FSL N1-017 ∆lytB + pPL2-lytB-6xHis (10403S) This study 
DP-L6795 HPB2262 ∆gcpE + pPL2-gcpE-6xHis (10403S) This study 
DP-L6796 HPB2262 ∆lytB + pPL2-lytB-6xHis (10403S) This study 
DP-L6797 EGD-e ∆gcpE + pPL2-gcpE-6xHis (10403S) This study 
DP-L6798 EGD-e ∆lytB + pPL2-lytB-6xHis (10403S) This study 
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Table 3.3: E. coli strains 
 
Strain Description Reference 
DP-L6799 pKSV7x-gcpE (EGD-e) This study 
DP-L6800 pKSV7x-lytB (EGD-e) This study 
DP-L6801 pKSV7x-gcpE (FSL N1-017) This study 
DP-L6802 pKSV7x-lytB (FSL N1-017) This study 
DP-L6803 pKSV7x-gcpE (HPB2262) This study 
DP-L6804 pKSV7x-lytB (HPB2262) This study 
DP-L6805 pPL2-gcpE-6xHis (10403S) This study 
DP-L6806 pPL2-lytB-6xHis (10403S) This study 
 
 
Table 3.4: Primers used for qPCR 
 
Primer Sequence Description 
oEDL142 gggagcgttggactacttcc F qPCR primer for dxr 
oEDL143 cttttctttcgccgaacgca R qPCR primer for dxr 
oEDL177 ctaatgatggacgcgctgga F qPCR primer for lisR 
oEDL178 ttgtttcacttggcgcacac R qPCR primer for lisR 
oEDL179 caagcttttgggttccgcaa F qPCR primer for qoxA 
oEDL180 cgccgttgaagtttgcgtta R qPCR primer for qoxA 
oEDL188 ttacatacaccggagagcgc F qPCR primer for lmo0292 
oEDL189 tttgtagaactcgcctcggc R qPCR primer for lmo0292 
oEDL369 cacacggcagaacaaaagacac F qPCR primer for lmo0484 
oEDL370 gattgcatttcctacgatgcctttc R qPCR primer for lmo0484 
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Concluding Remarks and Future Directions 
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4.1 Summary of results 
 In this study, we demonstrate that the nonmevalonate pathway is sufficient for 
anaerobic growth in L. monocytogenes. We confirmed previous work showing that the 
mevalonate pathway is essential aerobically, but found that anaerobic conditions 
allowed a knockout in the mevalonate pathway to grow, albeit with a severe growth 
defect. Additionally, multiple mechanisms were identified by which the slow anaerobic 
growth in ∆hmgR could be increased, using both targeted genetic approaches and 
unbiased suppressor mutation analysis.  
In the targeted approach, multiple lineage I L. monocytogenes strains were found 
to grow significantly faster using the nonmevalonate pathway than 10403S. This growth 
difference was due to three point mutations in the nonmevalonate pathway enzyme 
GcpE that are present in the clinical isolates, but not 10403S: K291T, E293K, and 
V294A. Single point mutants did not increase growth, suggesting that all three 
mutations in GcpE needed to occur in tandem to have an effect. When these mutations 
were made in a 10403S ∆hmgR strain, its growth rate increased to the same as the 
clinical isolates, but the amount of HMBPP produced did not significantly change. These 
observations demonstrate that HMBPP concentration is not directly proportional to 
anaerobic growth rate and suggest that further work is needed to fully understand 
metabolism using the nonmevalonate pathway in L. monocytogenes. 
In addition to examining the specific nonmevalonate pathway genes, we asked 
whether other mutations could impact growth by sequentially passaging ∆hmgR to 
isolate fast-growing suppressor mutants. The highest frequency mutations were in the 
protein LisK, a sensor histidine kinase that, in combination with the response regulator 
LisR, forms the two-component system LisRK. Deleting lisK from ∆hmgR resulted in an 
extremely growth-impaired strain, which suggests that the point mutations increase or 
alter, rather than disrupt, LisRK signaling. We were unable to identify specific changes 
in LisRK-regulated genes that could impact the nonmevalonate pathway, but more 
intentionally examining the LisRK regulon may be an interesting area of further study, 
and could help reveal other methods by which growth on the nonmevalonate pathway 
could be improved. 
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4.2 Remaining questions 
 
4.2.1 The role of the nonmevalonate pathway in L. monocytogenes biology 
 At the beginning of this work, we set out to answer two major questions about 
isoprenoid precursor biosynthesis pathways in L. monocytogenes. First, can L. 
monocytogenes use the nonmevalonate pathway for growth? We demonstrated that the 
nonmevalonate pathway is sufficient for growth anaerobically. The precise reasons why 
L. monocytogenes needs to be cultured anaerobically for the nonmevalonate pathway 
to function are not clear, but it may stem from a faulty iron-sulfur cluster biosynthesis 
pathway, an inability to keep the bacterial cytosol reduced, or metabolic changes 
anaerobically that require reallocation of pathway precursors like acetyl-CoA. However, 
answering this question about isoprenoid precursor pathways in L. monocytogenes will 
contribute to our broader understanding of isoprenoid metabolism in bacteria. The vast 
majority of bacteria have one of the two pathways, but there has only been speculation 
as to why one pathway might be favored or beneficial over the other in a bacterial 
species. If we understand the conditions or signals that lead to greater flux through the 
nonmevalonate pathway, that may point towards more generalizable conditions that 
other bacteria experience. 
 The second, and seemingly more important question, is still unanswered: why 
does L. monocytogenes maintain two pathways, when a single pathway is sufficient for 
the vast majority of cells? Is it simply that L. monocytogenes is in the process of losing 
both pathways and we examined it during this transitional period? Our assumption has 
been that it would be extremely unlikely for humans, nonhuman primates, or other 
Vg9Vd2 T-cell producing organisms to have a strong enough selective pressure to 
maintain the nonmevalonate pathway and HMBPP production, but this may be a 
possibility. Getting a mechanistic understanding of why the nonmevalonate pathway 
functions anaerobically may point towards the pathway’s broader role for L. 
monocytogenes biology. Alternatively, while mice do not have BTN3A1 or the Vg9Vd2 T-
cell receptor, there is still a possibility that different receptors and cell types could work 
in a functionally analogous manner to recognize bacterial phosphoantigens. 
 
4.2.2 The nonmevalonate pathway and biosynthesis of iron-sulfur clusters 
We found that the nonmevalonate pathway functions anaerobically, but have 
been unable to determine why it does not work aerobically and have been unable to 
isolate any suppressor mutants that grow aerobically. We hypothesize that the 
nonmevalonate pathway may be limited the fact that GcpE and LytB contain iron sulfur 
clusters, metal cofactors in proteins, which are sensitive to oxygen in purified proteins. 
However, many organisms exclusively have the nonmevalonate pathway and grow in 
the presence of oxygen, which suggests that the oxygen sensitive nature of iron-sulfur 
clusters can change in a cell. Other circumstantial evidence also suggests that L. 
monocytogenes may be a unique organism in terms of iron-sulfur clusters. A large 
number of bacterial pathogens have iron-sulfur cluster containing virulence factors and 
use them to sense the iron and oxygen concentration changes that occur during 
infection (105). Despite the apparent practicality of iron-sulfur clusters for sensing the 
environment, no iron-sulfur cluster containing virulence factors have been identified in L. 
monocytogenes to date.  
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Three different iron-sulfur biosynthesis pathways have been identified in bacteria, 
termed Isc, Suf, and Nif. All of these multi-gene pathways can synthesize iron-sulfur 
clusters, but in organisms that encode more than one pathway, the Isc system is 
considered to be the housekeeping pathway while the Suf system operates better under 
stress conditions. E. coli encode both the Isc and Suf system, but Bacillus subtilis and L. 
monocytogenes only have a single Suf-like system. A series of exciting genetic studies 
in E. coli and B. subtilis showed that iron-sulfur biosynthesis pathways are only 
essential for the nonmevalonate pathway (59,60). E. coli and B. subtilis mutants lacking 
the capability to synthesize iron-sulfur clusters had growth defects, but these data show 
that the iron-sulfur clusters found in GcpE (also called IspG) and LytB (also IspH) are 
the only truly essential iron-sulfur clusters in each bacteria,. Considering the wide 
distribution of iron-sulfur cluster containing enzymes across all cellular processes, this is 
a remarkable discovery that emphasizes the central importance of isoprenoid precursor 
pathways (106). 
To explore whether L. monocytogenes has a deficiency synthesizing iron-sulfur 
clusters, we complemented the iron-sulfur cluster biosynthesis operons from both E. coli 
and B. subtilis into ∆hmgR and expressed the operons under both their native 5’ UTR 
and a constitutively active 5’ UTR. Preliminary data indicate that constitutive expression 
of the B. subtilis SUF-like system may increase ∆hmgR growth rate anaerobically 
(Kathleen Navas, unpublished data), but further work needs to be done to better 
characterize iron-sulfur cluster biosynthesis in L. monocytogenes.  
 
4.2.3 The role of Vg9Vd2 T-cells in bacterial infections and adaptive immunity 
 Peripheral to this study has been the question of how Vg9Vd2 T-cell activation 
influences the outcome of primary infections, as well as the development of adaptive 
immunity against a pathogen. Activated Vg9Vd2 T-cells can have cytotoxic activity 
against HMBPP-presenting cells, which conceivably helps limit the spread of bacterial 
infections. However, it is not clear whether a rapid, innate-like response sacrifices 
stronger adaptive immunity by limiting antigen production or inhibiting the development 
of memory T-cells. In a handful of primate studies using L. monocytogenes as a vaccine 
platform, they have observed that reducing HMBPP production by deleting gcpE 
improves protection against M. tuberculosis. These studies were conducted using 
10403S, and our data suggest that there is a very modest difference in HMBPP 
production between WT and ∆gcpE. Using the discoveries presented here, it would be 
intriguing to engineer a 10403S strain that produces HMBPP at similar or greater levels 
as the lineage I strains and examine whether that strain is less effective at inducing 
immunity than WT 10403S. 
 Metabolically engineering HMBPP production in L. monocytogenes and 
conducting the necessary studies in primate models would be both technically 
challenging and expensive. However, in the absence of a reliable humanized mouse 
model or other model organism with Vg9Vd2 T-cells, there are distinct limits on how 
much we can learn about these cells. Immunologists continue to use mouse models to 
understand the immune system and they continue to learn greater and greater details 
about how the mouse immune system works. One wonders though, how the absence of 
entire cell types will impact our ability to translate basic research discoveries into 
practical therapies in the future. 
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4.2.4 Engineering isoprenoid precursor pathways in other bacterial pathogens 
 In terms of infectious disease prevention, vaccines are the gold standard for both 
cost efficiency and long-term efficacy. Unfortunately, the past several decades of 
research have largely failed to yield progress in this area, with the exception of the 
pneumococcal vaccine. While some of this may be traced to decreased interest or 
investment in vaccine development, I would question whether our models need to 
advance to make progress. Decades of work and countless dollars have been spent 
trying to develop vaccines against Chlamydia trachomatis and Mycobacterium 
tuberculosis, without success. Intriguingly, both pathogens have the nonmevalonate 
pathway, they latently infect a host, and positive results in mice have not translated well 
into clinical trials. 
 At the same time as we use L. monocytogenes to advance our understanding of 
Vg9Vd2 T-cells, it would be interesting to begin engineering these pathogens so that 
they do not produce HMBPP. If Vg9Vd2 T-cell activation reduces the initial disease 
severity, but inhibits adaptive immunity, would replacing the nonmevalonate pathway 
with the mevalonate pathway increase vaccine efficacy? In particular, M. marinum is 
one of the few organisms other than L. monocytogenes that has both isoprenoid 
precursor pathways, so it is conceivable that the mevalonate pathway could be cloned 
into M. tuberculosis or the vaccine strain, Bacillus Calmette-Guérin. This line of 
questioning also encounters the challenge of adequately modeling Vg9Vd2 T-cell 
functions in the immune system, but the potential benefits derived from improving the M. 
tuberculosis vaccine can hardly be understated. 
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4.3 Concluding thoughts 
 
 There are several broad aspects of the L. monocytogenes field that I hope will 
advance during the next generation of graduate students. Since 2015, an assortment of 
students and postdocs have made a half-hearted effort to develop CRISPR-based 
genetic tools in Listeria, but no one has ever invested enough time to really get it to 
work. In addition to the “we should have it because Jennifer Doudna is at Berkeley” 
angle, it would be a leap forward from our current cloning genetic tools. Not only would 
CRISPR allow us to perform genetic screens more rapidly, but there are entire 
categories of genetic mutants that simply cannot be made with allelic exchange. Any 
strain that has a growth defect is rapidly outcompeted during the cloning process, which 
makes it very challenging to create mutants that have any sort of a growth defect. In the 
same vein, it would be extremely valuable to develop transposon sequencing (TnSeq) in 
L. monocytogenes. The value of transposon sequencing is obvious, but similar to our 
efforts with CRISPR, several lab members have briefly attempted to make it work, 
without fully committing to the tool-building endeavor. 
 
 For this work in particular, I hope that the discoveries presented here will 
contribute to the broader scientific endeavor. I envisioned ‘solving’ the mevalonate and 
nonmevalonate pathway question during my first two years, identifying an HMBPP-
responsive cell type in mice the following year, and then spending the rest of my time 
engineering isoprenoid precursor pathways in Mycobacterium marinum and 
Mycobacterium tuberculosis to make a better vaccine strain. This did not happen, but so 
goes science. 
 
 Prior to every lab retreat, Dan has suggested that we play a game of sorts, 
asking us to envision what our science will look like five, ten, or twenty years into the 
future. We never have, inevitably sliding into the finest idle chatter over beers on his 
back patio, so here seems as good a place as any to speculate about the future of this 
science. Five years from now, in 2024, we will have completely solved the 
nonmevalonate pathway in L. monocytogenes. Whether it requires point mutations in 
other enzymes, activation of additional regulatory proteins, the bug’s inability to 
synthesize iron-sulfur clusters, or some presently unknown factor, I believe that we will 
understand why L. monocytogenes has both pathways. Ten years from now, in 2029, 
we will have completed a study using rationally designed bacterial strains in nonhuman 
primates. The possibility that one of these strains should be tested in primates has been 
raised from the very beginning of this work, but limited model systems and the sheer 
cost of nonhuman primate work mean that any study requires a highly coordinated effort 
to succeed. The study won’t necessarily use a L. monocytogenes strain, as there is and 
presumably still will be, far more incentive to improve the BCG vaccine rather than 
develop a L. monocytogenes vaccine from scratch. Twenty years from now, in 2039, 
what’s old is now new. Despite the attempt, and failure, to use L. monocytogenes as a 
personalized immunotherapy platform, aberrant Vg9Vd2 T-cell stimulation is the real 
reason it failed in clinical trials. Having resolved that issue, personalized 
immunotherapies have become commonplace. Other technological advances mean that 
a cancer can be sequenced, artificial intelligence identifies a collection of 
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immunostimulatory epitopes, and an antigen-containing plasmid can be printed, all in 
the span of a week with little to no human intervention. 
 
 In many ways it seems like there are two major categories of scientific projects: 
ones that pick up a thread and ones that continue pulling on a thread. The Portnoy Lab 
has been pulling on the thread of L. monocytogenes virulence factors for decades, 
developing tools to understand virulence and revealing the deepest minutiae of ActA 
and LLO. As scientists in the lab have picked up new threads, it has oftentimes required 
someone new to follow up on an initial discovery before reaching a major breakthrough. 
One could argue that the discovery of multidrug resistance transporters (107) was a key 
piece to help with the identification of c-di-AMP (12), the discovery of STING (108), and 
much more work on L. monocytogenes metabolism (86,109). Similarly, significant effort 
was required to find that PrfA is activated in a reducing environment (76). The broad 
conclusion, that L. monocytogenes is redox sensitive, was again fundamental to the 
discovery of a completely novel extracellular electron transport chain in L. 
monocytogenes (79). believe that this work on isoprenoid precursors falls into the first 
category, as it built upon no more than a handful of published papers. It would be wrong 
to assume that this work will have a fraction of the impact as the studies mentioned 
above, but I hope that it will. At last however, my time in the lab is done, so the 
demonstration of this work’s significance will be left as an exercise for the reader. 
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Supplementary Table 1: Full strain catalog 
 Organism 
Genomic 
Alteration Plasmid Details 
Plasmid 
Backbone Notes 
EDL001 L. monocytogenes WT 10403S   
WT strain obtained from AW (probably 
AW106, DP-L6253) 
EDL002 L. monocytogenes ∆actA∆inlB∆lytB   Obtained from Aduro 
EDL003 E. coli (XL1 Blue) pKSV7oriT-lytB pKSV7, unaltered pKSV7 
Obtained from Aduro (pBHE3404), plated on 
Lb-Carb? 
EDL004 E. coli (XL1 Blue) pKSV7oriT-gcpE pKSV7, unaltered pKSV7 
Obtained from Aduro (pBHE3379), plated on 
Lb-Carb? 
EDL005 L. monocytogenes ∆actA∆inlB∆gcpE   Obtained from Aduro 
EDL006 L. monocytogenes ∆actA∆inlB   Lab stock: DP-L6054 
EDL007 E. coli (SM10) pKSV7oriT pKSV7, unaltered pKSV7  
EDL008 E. coli (SM10) pKSV7oriT-∆lytB pKSV7, unaltered pKSV7 In-frame, allelic exchange 
EDL009 E. coli (SM10) pKSV7oriT-∆gcpE pKSV7, unaltered pKSV7 In-frame, allelic exchange 
EDL010 E. coli (SM10) pKSV7oriT-∆hmgR pKSV7, unaltered pKSV7 In-frame, allelic exchange 
EDL011 L. monocytogenes ∆gcpE    
EDL012 L. monocytogenes ∆lytB    
EDL013 L. monocytogenes ∆hmgR   Add 250 µM /1 mM mevalonate to media 
EDL014 L. monocytogenes ∆actA∆lytB    
EDL015 L. monocytogenes ∆actA∆gcpE    
EDL016 L. monocytogenes ∆actA∆hmgR   Add 250 µM /1 mM mevalonate to media 
EDL017 L. monocytogenes ∆hmgR∆gcpE   Add 250 µM /1 mM mevalonate to media 
EDL018 L. monocytogenes ∆hmgR∆lytB   Add 250 µM /1 mM mevalonate to media 
EDL019 L. monocytogenes None  Unknown DP-L3903, JP075 
EDL020 L. monocytogenes ∆hmgR  pPL2x  
EDL021 E. coli (SM10) pPL2x-MEVk Lmo0010-0012 pPL2x Contains Lmo0010-Lmo0012 
EDL022 E. coli (SM10) pKSV7-MEVk Lmo0010-0012 pKSV7 Contains Lmo0010-Lmo0012 
EDL023 E. Coli (XL1 Blue)   pPL2x Use EDL032 for Toxin/Antitoxin in plasmid 
EDL024 E. coli (SM10) pPL2x-hmgR hmgR pPL2x Complements ∆hmgR/lmo0825 
EDL025 
L. monocytogenes 
(clinical isolate)    Clinical isolate FSL N1-017, PL300 from Pete 
EDL026 
L. monocytogenes 
(clinical isolate)    
Clinical isolate HPB2262, PL309/Aureli 1997 
from Pete 
EDL027 L. monocytogenes ∆prfA   Obtained from MLR 
EDL028 L. monocytogenes prfA*   Obtained from MLR 
EDL029 L. monocytogenes prfA*∆hmgR   Add 250 µM /1 mM mevalonate to media 
EDL030 L. monocytogenes ∆prfA∆hmgR None None Add 250 µM /1 mM mevalonate to media 
EDL031 L. monocytogenes ∆hmgR pPL2x-hmgR pPL2x ∆hmgR complemented with pPL2x 
EDL032 E. coli (DB3.1) None None pPL2x AW616 
EDL033 E. coli (DB3.1) None None pKSV7x AW644 
EDL034 E. coli (SM10) 
pPL2x-lytB (B. 
subtilis)  pPL2x 
lytB from B. subtilis to complement 
nonmevalonate pathway 
EDL035 L. monocytogenes ∆hmgR∆lytB 
pPL2x-lytB (B. 
subtilis) pPL2x 
lytB from B. subtilis to complement 
nonmevalonate pathway 
EDL036 B. subtilis 168    From AW373, dies at 4ºC 
EDL037 L. monocytogenes ∆actA    
EDL038 L. monocytogenes 
∆hmgR (FSL N1-
017)   
Clinical isolate FSL N1-017 with hmgR 
deleted, not Strep resistant 
EDL039 L. monocytogenes C484A (LLO)   DP-L4351 from JP11 
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EDL040 L. monocytogenes L461T (LLO)   DP-L4017 
EDL041 L. monocytogenes ∆hly   DP-L2161 
EDL042 L. monocytogenes ∆hly∆plcA∆plcB   DP-L2319 
EDL043 L. monocytogenes ∆actA L461T (LLO)   DP-L4038 
EDL044 L. monocytogenes holin/lysin   DP-L5750 
EDL045 L. monocytogenes ∆hmgR   
Suppressor #1 selected in anaerobic BHI 
broth, AW002A; lisK* 826G>A 
EDL046 L. monocytogenes ∆hmgR   
Suppressor #2 selected in anaerobic BHI 
broth, AW002B 
EDL047 L. monocytogenes ∆hmgR   
Suppressor #3 selected in anaerobic BHI 
broth, AW002C; lisK* 778T>G 
EDL048 L. monocytogenes ∆hmgR   
Suppressor #4 selected in anaerobic BHI 
broth, AW002D; lisK* 106A>G 
EDL049 L. monocytogenes ∆hmgR   
Suppressor #5 selected in anaerobic BHI 
broth, AW002E 
EDL050 L. monocytogenes ∆hmgR   
Suppressor #6 selected in anaerobic BHI 
broth, AW002F, frameshift in lmo1505 
EDL051 E. coli (SM10) pPL2x-lytB (FSL)  pPL2x lytB from clinical isolate FSL N1-017 
EDL052 L. monocytogenes ∆hmgR∆lytB pPL2x-lytB (FSL)  lytB from clinical isolate FSL N1-017 
EDL053 
L. monocytogenes 
WSLC 1001 None   Potentially phage P40 sensitive, DP-L3671 
EDL054 
L. ivanovii WSLC 
3009 None   Potentially phage P40 sensitive, DP-L393 
EDL055 
E. coli (XL1 
Blue?) None None pJZ037 
Adapted from pKSV7 and contains a 
transposase for generating Lmo transposon 
libraries 
EDL056 L. monocytogenes ErmR::Tn917    Erm Resistance transposon, DP-L3903 
EDL057 L. monocytogenes    Mack (derived from EGD), DP-L861 
EDL058 L. monocytogenes 
WT_pTBL1 
menB::himar1   
JP126, WT_pTBL1 Mutant with Himar1 in 
lmo1673 (Raw Screen Hit)(Seq JPS555) 
EDL059 L. monocytogenes 
WT_pTBL1 
cydA::himar1   
JP127, WT_pTBL1 Mutant with Himar1 in 
lmo2718 (Raw Screen Hit)(Seq JPS556) 
EDL060 L. monocytogenes 
WT_pTBL1 
lmo1930::himar1   
JP128, WT_pTBL1 Mutant with Himar1 in 
lmo1930 (Raw Screen Hit)(Seq JPS557) 
EDL061 L. monocytogenes 
WT_pTBL1 
cydB::himar1   
JP129, WT_pTBL1 Mutant with Himar1 in 
lmo2717 (Raw Screen Hit)(Seq JPS558) 
EDL062 L. monocytogenes 
WT_pTBL1 
mutS::himar1   
JP130, WT_pTBL1 Mutant with Himar1 in 
lmo1403 (Raw Screen Hit)(Seq JPS560) 
EDL063 L. monocytogenes 
WT_pTBL1 
hemL::himar1   
JP131, WT_pTBL1 Mutant with Himar1 in 
lmo1553 (Raw Screen Hit)(Seq JPS564) 
EDL064 E. coli (SM10) pKSV7-lisK   
Two component system hit with suppressor 
analysis in ∆hmgR; 6 starting, 6 ending amino 
acids 
EDL065 L. monocytogenes 
∆gcpE, 
ErmR::Tn917   Erm resistant transposon from DP-L3903 
EDL066 L. monocytogenes ∆lytB, ErmR::Tn917   Erm resistant transposon from DP-L3903 
EDL067 L. monocytogenes 
∆hmgR, 
ErmR::Tn917   Erm resistant transposon from DP-L3903 
EDL068 E. coli (SM10)    KanR cassette replacing hmgR 
EDL069 L. monocytogenes    DP-L5480 
EDL070 L. monocytogenes    DP-L5481 
EDL071 L. monocytogenes    DP-L5482 
EDL072 L. monocytogenes    DP-L5483 
EDL073 L. monocytogenes    DP-L5484 
EDL074 L. monocytogenes ∆lisK   
6 starting + 6 ending amino acids, gene 
mutated in ∆hmgR suppressors 
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EDL075 L. monocytogenes ∆hmgR ∆lisK   
In-frame deletion of hmgR and lisK using 
pKSV7 
EDL076 L. monocytogenes ∆hmgR::KanR   
In-frame replacement of hmgR with a 
Kanamycin resistance cassette 
EDL077 L. monocytogenes ∆mdrT   DP-L5446 
EDL078 L. monocytogenes ∆hmgR   
Contains 826G>A in lisK and himar1 
transposon at lmo1389 from TAP47 (phage 
lysate generated from RelAPQ background) 
EDL079 L. monocytogenes ∆hmgR   
Contains 778T>G in lisK and himar1 
transposon at lmo1389 from TAP47 (phage 
lysate generated from RelAPQ background) 
EDL080 L. monocytogenes ∆hmgR   
Contains 106A>G in lisK and himar1 
transposon at lmo1389 from TAP47 (phage 
lysate generated from RelAPQ background) 
EDL081 L. monocytogenes ∆hmgR ∆lisK pPL3-mCherry  mCherry driven by pHyper on pPL2 
EDL082 L. monocytogenes None pPL3-mCherry  mCherry driven by pHyper on pPL2 
EDL083 L. monocytogenes ∆hmgR lisK*1   
Rederived lisK 826G>A mutation using lysate 
from EDL078, ∆hmgR lisK*1 
EDL084 L. monocytogenes ∆hmgR lisK*2   
Rederived lisK 778T>G mutation using lysate 
from EDL079, ∆hmgR lisK*3 
EDL085 L. monocytogenes ∆hmgR lisK*3   
Rederived lisK 106A>G mutation using lysate 
from EDL080, ∆hmgR lisk*4 
EDL086 E. coli  pJZ037  
MISLABELED IN STRAIN BOX, use for making 
transposon libraries in L. monocytogenes 
EDL087 L. monocytogenes 
∆hmgR, LacZ-
Tn917   
∆hmgR parent strain containing Tn917 
containing LacZ gene, use to screen for WT 
mutants that don't complement hmgR growth 
EDL088 E. coli (SM10)  pPL2x-Phyper-lisK  pPL2x containing lisK and Phyper promoter 
EDL089 L. monocytogenes ∆hmgR ∆lisK pPL2x-Phyper-lisK  
Complemented without the upstream RBS or 
downstream terminator, does not look like 
complementation by anaerobic growth 
EDL090 E. coli (SM10)  pKSV7x-lisRK  Deletes both components of LisRK 
EDL091 E. coli (SM10)  pPL2x-lisRK  
Complements lisRK with the upstream RBS 
and downstream terminator 
EDL092 L. monocytogenes ∆hmgR ∆lisK pPL2x-lisRK  
lisRK complemented with the upstream RBS 
and downstream terminator, in a ∆hmgR∆lisK 
background (should redo in ∆lisRK) 
EDL093 L. monocytogenes ∆lisRK   
In-frame deletion of TCS lisRK using allelic 
exchange 
EDL094 L. monocytogenes 
∆hmgR 
clpC::himar1   
Transposon obtained from SL reducing agent 
screen using himar1 
EDL095 E. coli (SM10)  pPL2x-Phyper-lisR pPL2x 
Overexpresses lisR to (hopefully) phenocopy 
constitutive activation of lisK 
EDL096 L. monocytogenes  pPL2x-Phyper-lisR pPL2x 
Overexpresses lisR to (hopefully) phenocopy 
constitutive activation of lisK 
EDL097 L. monocytogenes ∆hmgR pPL2x-Phyper-lisR pPL2x 
Overexpresses lisR to (hopefully) phenocopy 
constitutive activation of lisK 
EDL098 E. coli (SM10)  pKSV7x-dxr-His pKSV7x Includes dxr gene, His tag, 1000bp after gene 
EDL099 L. monocytogenes lmo0013::himar1   
quinol oxidase polypeptide II, rederived 
transposon (1-34) from screen hit done by 
VED, overexpressed in 4b serotypes 
extracellularly 
EDL100 L. monocytogenes lmo2529::himar1   
ATPsynthase F1 beta subunit, rederived 
transposon (2-37?) from screen hit done by 
VED, growth defect in BHI 
EDL101 L. monocytogenes lmo0014::himar1   
cytochrome aa3 quinol oxidase subunit I, 
rederived transposon (2-49) from screen hit 
done by VED 
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EDL102 L. monocytogenes lmo0031::himar1   
LacI family transcriptional regulator, rederived 
transposon (2-33) from screen hit done by 
VED 
EDL103 L. monocytogenes lmo1293::himar1   
glycerol-3-phosphate dehydrogenase, 
rederived transposon (2-39) from screen hit 
done by VED 
EDL104 L. monocytogenes lmo2532::himar1   
ATP synthase F1 subunit delta, rederived 
transposon (2-47) from screen hit done by VED, 
growth defect in BHI 
EDL105 L. monocytogenes lmo0401::himar1   
alpha-mannosidase, rederived transposon (2-
69) from screen hit done by VED 
EDL106 L. monocytogenes lmo0015::himar1   
cytochrome aa3 quinol oxidase subunit III, 
rederived transposon (2-41) from screen hit 
done by VED 
EDL107 L. monocytogenes lmo1389::himar1   
Contains himar1 transposon at lmo1389 from 
TAP47 (phage lysate generated from EDL083 
background) 
EDL108 L. monocytogenes 
lisK 826G>A, 
lmo1389::himar1   
Contains 826G>A in lisK and himar1 
transposon at lmo1389 from TAP47 (phage 
lysate generated from EDL083 background) 
EDL109 L. monocytogenes 
lisK 778T>G, 
lmo1389::himar1   
Contains 778T>G in lisK and himar1 
transposon at lmo1389 from TAP47 (phage 
lysate generated from EDL084 background) 
EDL110 L. monocytogenes 
lisK 106A>G, 
lmo1389::himar1   
Contains 106A>G in lisK and himar1 
transposon at lmo1389 from TAP47 (phage 
lysate generated from EDL085 background) 
EDL111 E. coli (SM10)  pPL2x-Phyper-dxr pPL2x 
"Overexpresses" dxr (lmo1317) driven by 
pHyper promoter, but contains 100bp from 
gene itself 
EDL112 L. monocytogenes ∆hmgR   
∆hmgR suppressor #1 selected in anaerobic 
BHI broth, second round 
EDL113 L. monocytogenes ∆hmgR   
∆hmgR suppressor #2 selected in anaerobic 
BHI broth, second round (no lisK suppressor) 
EDL114 L. monocytogenes ∆hmgR   
∆hmgR suppressor #3 selected in anaerobic 
BHI broth, second round (no lisK suppressor) 
EDL115 L. monocytogenes ∆hmgR   
∆hmgR suppressor #4 selected in anaerobic 
BHI broth, second round (no lisK suppressor) 
EDL116 L. monocytogenes ∆hmgR   
∆hmgR suppressor #5 selected in anaerobic 
BHI broth, second round (no lisK suppressor) 
EDL117 L. monocytogenes ∆hmgR   
∆hmgR suppressor #6 selected in anaerobic 
BHI broth, second round (no lisK suppressor) 
EDL118 L. monocytogenes ∆hmgR   
∆hmgR suppressor #7 selected in anaerobic 
BHI broth, second round (lisK 826G>A) 
EDL119 L. monocytogenes ∆hmgR   
∆hmgR suppressor #8 selected in anaerobic 
BHI broth, second round (bad F sequencing) 
EDL120 L. monocytogenes ∆hmgR   
∆hmgR suppressor #9 selected in anaerobic 
BHI broth, second round (mixed population at 
522?) 
EDL121 L. monocytogenes ∆hmgR   
∆hmgR suppressor #10 selected in anaerobic 
BHI broth, second round (no lisK suppressor) 
EDL122 L. monocytogenes ∆hmgR   
∆hmgR suppressor #11 selected in anaerobic 
BHI broth, second round (no lisK suppressor) 
EDL123 L. monocytogenes WT pPL2x-Phyper-dxr pPL2x BAD PLASMID 
EDL124 L. monocytogenes ∆lisRK pPL2x-Phyper-dxr pPL2x BAD PLASMID 
EDL125 L. monocytogenes ∆hmgR pPL2x-Phyper-dxr pPL2x BAD PLASMID 
EDL126 L. monocytogenes ∆hmgR ∆lisK pPL2x-Phyper-dxr pPL2x BAD PLASMID 
EDL127 E. coli (SM10)  pPL2x-Phyper-dxr pPL2x 
Overexpresses dxr (lmo1317) driven by 
pHyper promoter 
EDL128 L. monocytogenes WT pPL2x-Phyper-dxr pPL2x 
Overexpresses dxr (lmo1317) driven by 
pHyper promoter 
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EDL129 L. monocytogenes ∆hmgR pPL2x-Phyper-dxr pPL2x 
Overexpresses dxr (lmo1317) driven by 
pHyper promoter 
EDL130 L. monocytogenes WT 
pPL2x-Phyper-
uppS pPL2x 
Overexpresses uppS (lmo1315) driven by 
pHyper promoter 
EDL131 L. monocytogenes ∆hmgR 
pPL2x-Phyper-
uppS pPL2x 
Overexpresses uppS (lmo1315) driven by 
pHyper promoter 
EDL132 E. coli (SM10)  
pPL2x-Phyper-
uppS+dxr pPL2x 
Overexpresses uppS (lmo1315) and dxr 
(lmo1317) driven by pHyper promoter 
EDL133 E. coli (SM10)  
pPL2x-PactA-
hmgR  
hmgR under control of an ActA promoter 
(promoter copied from PactA-cre construct) 
EDL134 L. monocytogenes ∆actA ∆inlB   
LADD strain constructed by Pete Lauer and 
Bill Hanson (probably DP-L6053) 
EDL135 L. monocytogenes ∆hmgR 
pPL2x-PactA-
hmgR  
hmgR under control of an ActA promoter 
(promoter copied from PactA-cre construct) 
EDL136 L. monocytogenes ∆hmgR ∆lisK 
pPL2x-PactA-
hmgR  
hmgR under control of an ActA promoter 
(promoter copied from PactA-cre construct) 
EDL137 L. monocytogenes ∆hmgR 
pPL2x-Phyper-
uppS+dxr  
Overexpresses uppS (lmo1315) and dxr 
(lmo1317) driven by pHyper promoter, No 
increased growth rate anaerobically 
EDL138 E. coli (SM10)  pPL2e-PactA-cre  DP-E6233, pPL2e-PactA-cre 
EDL139 E. coli (SM10)  
pPL2e-Phyper-T1 
terminator-hmgR pPL2e 
hmgR under control of an ActA promoter but 
contains T1 terminator IN FRONT of gene 
EDL140 E. coli (SM10)  
pKSV7x-hmgR 
(HPB2262)  
Knocks out hmgR (6 AA at start and end) in 
strain HPB2262 
EDL141 E. coli (SM10)  
pKSV7x-gcpE 
(FSL N1-017)  
Knocks out gcpE (6 AA at start and end) in 
strain FSL N1-017 
EDL142 E. coli (SM10)  
pKSV7x-lytB (FSL 
N1-017)  
Knocks out lytB (6 AA at start and end) in 
strain FSL N1-017 
EDL143 
L. monocytogenes 
(HPB2262) ∆hmgR    
EDL144 
L. monocytogenes 
(FSL N1-017) ∆gcpE    
EDL145 
L. monocytogenes 
(FSL N1-017) ∆lytB    
EDL146 E. coli (SM10)  
pPL2e-Pmpl-
hmgR  
hmgR under control of mpl promoter, built in 
pPL2e 
EDL147 E. coli (SM10)  
pPL2e-PinlA-
hmgR  
hmgR under control of inlA promoter, built in 
pPL2e 
EDL148 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor #2, generated by 
plating anaerobically -MEV 
EDL149 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor #1, generated by 
plating anaerobically -MEV 
EDL150 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor #3, generated by 
plating anaerobically -MEV 
EDL151 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor #4, generated by 
plating anaerobically -MEV 
EDL152 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor 1D, generated by 
plating anaerobically -MEV, grew up in 2 days 
EDL153 E. coli (SM10)  NONE  
Original strain obtained from Rich Calendar, 
used to remake competent cells from the 
Berkeley QB3 
EDL154 
L. monocytogenes 
(HPB2262)    
Strep resistant clinical isolate, no other genetic 
mutations 
EDL155 
L. monocytogenes 
(FSL N1-017)    
Strep resistant clinical isolate, no other genetic 
mutations 
EDL156 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor 2A, generated by 
plating anaerobically -MEV 
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EDL157 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor 2B, generated by 
plating anaerobically -MEV 
EDL158 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor 2C, generated by 
plating anaerobically -MEV 
EDL159 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor 3A, generated by 
plating anaerobically -MEV 
EDL160 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor 3B, generated by 
plating anaerobically -MEV 
EDL161 L. monocytogenes ∆hmgR ∆lisK   
Non-lysing suppressor 3C, generated by 
plating anaerobically -MEV 
EDL162 E. coli (SM10)  
pKSV7x-
hmgR::ErmR pKSV7x 
Replacing hmgR gene with Erm resistance 
cassette from pPL2e 
EDL163 E. coli (SM10)  
pKSV7x-gcpE 
(HPB2262) pKSV7x 
Deletes gcpE from clinical isolate HPB2262, 6 
AA at front and end (APL) 
EDL164 E. coli (SM10)  
pKSV7x-lytB 
(HPB2262) pKSV7x 
Deletes lytB from clinical isolate HPB2262, 6 
AA at front and end (APL) 
EDL165 
L. monocytogenes 
(EGDe)    DP-L197 
EDL166 E. coli (SM10)  
pKSV7x-gcpE 
(EGDe) pKSV7x 
Deletes gcpE from EGDe, 6 AA at front and 
end 
EDL167 E. coli (SM10)  
pKSV7x-lytB 
(EGDe) pKSV7x Deletes lytB from EGDe, 6 AA at front and end 
EDL168 E. coli (SM10)  
pKSV7x-hmgR 
(EGDe) pKSV7x 
Deletes hmgR from EGDe, 6 AA at front and 
end 
EDL169 L. monocytogenes hmgR::ErmR   
Replacing hmgR gene with Erm resistance 
cassette from pPL2e 
EDL170 E. coli (SM10)  
pPL2x-pNative-
gcpE-6xHis 
(10403S) pPL2x 
Complements gcpE from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL171 E. coli (SM10)  
pPL2x-pNative-
lytB-6xHis 
(10403S) pPL2x 
Complements lytB from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL172 L. monocytogenes ∆gcpE 
pPL2x-pNative-
gcpE (10403S) pPL2x 
Complements gcpE from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL173 L. monocytogenes ∆lytB 
pPL2x-pNative-
lytB (10403S) pPL2x 
Complements lytB from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL174 
L. monocytogenes 
(EGDe) ∆hmgR   
Deletes hmgR from EGDe, 6 AA at front and 
end 
EDL175 
L. monocytogenes 
(FSL N1-017) ∆gcpE 
pPL2x-pNative-
gcpE (10403S) pPL2x 
Complements gcpE from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL176 
L. monocytogenes 
(FSL N1-017) ∆lytB 
pPL2x-pNative-
lytB (10403S) pPL2x 
Complements lytB from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL177 
L. monocytogenes 
(EGDe) ∆gcpE   
Deletes gcpE from EGDe, 6 AA at front and 
end (APL) 
EDL178 
L. monocytogenes 
(EGDe) ∆lytB   
Deletes lytB from EGDe, 6 AA at front and end 
(APL) 
EDL179 E. coli (SM10)  
pKSV7x-pHyper-
hmgR::ErmR pKSV7x 
Replacing hmgR gene with Erm resistance 
cassette from pPL2e, driven by pHyper 
promoter 
EDL180 
L. monocytogenes 
(EGDe) ∆gcpE 
pPL2x-pNative-
gcpE (10403S) pPL2x 
Complements gcpE from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL181 
L. monocytogenes 
(EGDe) ∆lytB 
pPL2x-pNative-
lytB (10403S) pPL2x 
Complements lytB from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
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EDL182 
L. monocytogenes 
(HPB2262) ∆gcpE   
Deletes gcpE from HPB2262, 6 AA at front 
and end 
EDL183 
L. monocytogenes 
(HPB2262) ∆lytB   
Deletes lytB from HPB2262, 6 AA at front and 
end 
EDL184 
L. monocytogenes 
(HPB2262) ∆gcpE 
pPL2x-pNative-
gcpE (10403S) pPL2x 
Complements gcpE from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL185 
L. monocytogenes 
(HPB2262) ∆lytB 
pPL2x-pNative-
lytB (10403S) pPL2x 
Complements lytB from 10403S on pPL2x 
using native promoter (200bp from TSS), 
allows for translation of His and Strep tags 
EDL186 E. coli (XL1 Blue)  None pJZ037 
Adapted from pKSV7 and contains a 
transposase for generating Lmo transposon 
libraries 
EDL187 E. coli (DB3.1)   pLIVCC  
EDL188 L. monocytogenes hly::Tn917   
Contains transposon in hly using lysate from 
DP-L2209, parental strain is EDL001 
EDL189 L. monocytogenes ∆gcpE hly::Tn917   
Contains transposon in hly using lysate from 
DP-L2209, parental strain is EDL011 
EDL190 L. monocytogenes ∆lytB hly::Tn917   
Contains transposon in hly using lysate from 
DP-L2209, parental strain is EDL012 
EDL191 E. coli (SM10)  
pPL2x-pNative-
lisK*1 pPL2x 
Complements lisK from EDL083 on pPL2x 
using native promoter (200bp from TSS) 
EDL192 E. coli (SM10)  
pPL2x-pNative-
lisK*2 pPL2x 
Complements lisK from EDL084 on pPL2x 
using native promoter (200bp from TSS) 
EDL193 E. coli (SM10)  
pPL2x-pNative-
lisK*3 pPL2x 
Complements lisK from EDL085 on pPL2x 
using native promoter (200bp from TSS) 
EDL194 L. monocytogenes ∆hmgR 
pPL2x-pNative-
lisK*1 pPL2x 
Complements lisK from EDL083 on pPL2x 
using native promoter (200bp from TSS) 
EDL195 L. monocytogenes ∆hmgR 
pPL2x-pNative-
lisK*2 pPL2x 
Complements lisK from EDL084 on pPL2x 
using native promoter (200bp from TSS) 
EDL196 L. monocytogenes ∆hmgR 
pPL2x-pNative-
lisK*3 pPL2x 
Complements lisK from EDL085 on pPL2x 
using native promoter (200bp from TSS) 
EDL197 E. coli (PPY)    PPY strain from Rob Nichols 
EDL198 
L. monocytogenes 
(HPB2262) Himar1   
Tn library prepared using pJZ037. Probably 
fairly poor coverage. 
EDL199 
L. monocytogenes 
(HPB2262) Himar1   
Tn library prepared using pJZ037. Probably 
fairly poor coverage. 
EDL200 E. coli (SM10)  pKSV7x-lisR pKSV7x 
Deletes lisR from 10403S, 6 AA at front and 
end 
EDL201 E. coli (SM10)  pKSV7x-hmgS pKSV7x 
Deletes hmgS from 10403S, 6 AA at front and 
end 
EDL202 L. monocytogenes ∆lisR   
LisR deleted from 10403S, 6 AA at front and 
end 
EDL203 L. monocytogenes ∆hmgS   
HmgS deleted from 10403S, 6 AA at front and 
end 
EDL204 L. monocytogenes ∆hmgS ∆hmgR   
HmgS and HmgR deleted from 10403S, 6 AA 
at front and end 
EDL205 L. monocytogenes ∆hmgR ∆lisR   
HmgR and LisR deleted from 10403S, 6 AA at 
front and end 
EDL206 L. monocytogenes WT   
Contains a Tn917- LTV3 insertion that leads to 
constitutive expression of lacZ gene 
EDL207 L. monocytogenes ∆hmgR   
Contains a Tn917- LTV3 insertion that leads to 
constitutive expression of lacZ gene 
EDL208 L. monocytogenes ∆hmgS   
Contains a Tn917- LTV3 insertion that leads to 
constitutive expression of lacZ gene 
EDL209 L. monocytogenes ∆hmgR ∆lisK   
Refreeze of EDL075 since old stock has 
decreased viability 
EDL210 L. monocytogenes ∆hmgR ∆lisR   
Contains a Tn917- LTV3 insertion that leads to 
constitutive expression of lacZ gene 
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EDL211 L. monocytogenes ∆hmgR ∆lisK   
Contains a Tn917- LTV3 insertion that leads to 
constitutive expression of lacZ gene 
EDL212 E. coli (SM10)  
pKSV7x-
lisRK::ErmR pKSV7x 
(should) Replace lisRK with ErmR cassette 
from pPL2e 
EDL213 
Enterococcus 
faecalis CG110  Tn916  
DP-E205, Strain used to conjugate Tn916 into 
L. monocytogenes from Enterococcus 
(http://www.pnas.org/content/pnas/86/14/5522.
full.pdf) 
EDL214 E. coli (SM10) ∆lmo0061 pKSV7x-lmo0061 pKSV7x 
pKSV7 to delete lmo0061 from 10403S, 6 AA 
at front and end 
EDL215 L. monocytogenes lisRK::ErmR   
Replaces lisRK with ErmR cassette from 
pPL2e 
EDL216 L. monocytogenes    Alex Louie WT Listeria 
EDL217 
E. coli (DH5-
alpha)    
DH5-alpha derivative expressing recombinase 
(from Chen) 
EDL218 
E. coli (DH5-
alpha)    
DH5-alpha expressing RegIII-gamma (from 
Freddy) 
EDL219 L. monocytogenes ∆lmo0061   
Lmo0061 deleted from 10403S, 6 AA at front 
and end (From Alex Louie WT, EDL216) 
EDL220 L. monocytogenes ∆hly ∆gcpE   
Knockout of gcpE derived from DP-L2161 ∆hly 
background 
EDL222 
L. monocytogenes 
(HPB2262, 
StrepR) ∆gcpE   Knockout of gcpE derived from EDL154 
EDL223 
L. monocytogenes 
(HPB2262, 
StrepR) ∆lytB   Knockout of lytB derived from EDL154 
EDL224 E. coli (DB3.1)  None  ccdB resistant E. coli with no plasmid 
EDL225 E. coli (Top10)  None  
ccdB sensitive E. coli with no plasmid, 
obtained from manufacturer 
EDL226 E. coli (DB3.1)  pPL2-ccdB pPL2x 
Removed some parts of MCS, keeps ccdB 
toxin intact 
EDL227 E. coli (Top10)  
FSL N1-017 
∆hmgR Library 1 pPL2-ccdB Approximately 500 colonies frozen down 
EDL228 E. coli (Top10)  
HPB2262 ∆hmgR 
Library 1 pPL2-ccdB Approximately 500 colonies frozen down 
EDL229 E. coli (SM10)  
FSL N1-017 
∆hmgR Library 1 pPL2-ccdB >2000 colonies frozen down 
EDL230 E. coli (SM10)  
HPB2262 ∆hmgR 
Library 1 pPL2-ccdB >2000 colonies frozen down 
EDL231 E. coli (Top10)  
FSL N1-017 
∆hmgR Library 2 pPL2-ccdB Approximately 700 colonies frozen down 
EDL232 E. coli (Top10)  
HPB2262 ∆hmgR 
Library 2 pPL2-ccdB Approximately 700 colonies frozen down 
EDL233 E. coli (SM10)  
pPL2-ispD 
(10403S) pPL2x 
ispD from 10403S complemented with ~200 
bp upstream promoter 
EDL234 E. coli (SM10)  pPL2-ispD (FSL) pPL2x 
ispD from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL235 E. coli (SM10)  pPL2-ispD (HPB) pPL2x 
ispD from HPB2262 complemented with ~200 
bp upstream promoter 
EDL236 E. coli (SM10)  
pPL2-ispD 
(Phyper) pPL2x 
ispD from 10403S complemented with Phyper 
promoter 
EDL237 E. coli (SM10)  
pPL2-gcpE 
(10403S) pPL2x 
gcpE from 10403S complemented with ~200 
bp upstream promoter 
EDL238 E. coli (SM10)  pPL2-gcpE (FSL) pPL2x 
gcpE from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL239 E. coli (SM10)  pPL2-gcpE (HPB) pPL2x 
gcpE from HPB2262 complemented with ~200 
bp upstream promoter 
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EDL240 E. coli (SM10)  
pPL2-gcpE 
(Phyper-HPB) pPL2x 
gcpE from HPB2262 complemented with 
Phyper promoter 
EDL241 E. coli (SM10)  
pPL2-lytB 
(10403S) pPL2x 
lytB from 10403S complemented with ~200 bp 
upstream promoter 
EDL242 E. coli (SM10)  pPL2-lytB (FSL) pPL2x 
lytB from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL243 E. coli (SM10)  pPL2-lytB (HPB) pPL2x 
lytB from HPB2262 complemented with ~200 
bp upstream promoter 
EDL244 E. coli (SM10)  
pPL2-lytB 
(Phyper-10403S) pPL2x 
lytB from 10403S complemented with Phyper 
promoter 
EDL245 E. coli (SM10)  
pPL2-lytB 
(Phyper-FSL,HPB) pPL2x 
lytB from FSL N1-017 complemented with 
Phyper promoter 
EDL246 E. coli (DB3.1)  pPL2gg pPL2x 
pPL2x modified to have Golden Gate BbsI cut 
sites 
EDL247 L. monocytogenes ∆hmgR 
pPL2-ispD 
(10403S) pPL2x 
ispD from 10403S complemented with ~200 
bp upstream promoter 
EDL248 L. monocytogenes ∆hmgR pPL2-ispD (FSL) pPL2x 
ispD from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL249 L. monocytogenes ∆hmgR pPL2-ispD (HPB) pPL2x 
ispD from HPB2262 complemented with ~200 
bp upstream promoter 
EDL250 L. monocytogenes ∆hmgR 
pPL2-ispD 
(Phyper) pPL2x 
ispD from 10403S complemented with Phyper 
promoter 
EDL251 L. monocytogenes ∆hmgR 
pPL2-gcpE 
(10403S) pPL2x 
gcpE from 10403S complemented with ~200 
bp upstream promoter 
EDL252 L. monocytogenes ∆hmgR pPL2-gcpE (FSL) pPL2x 
gcpE from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL253 L. monocytogenes ∆hmgR pPL2-gcpE (HPB) pPL2x 
gcpE from HPB2262 complemented with ~200 
bp upstream promoter 
EDL254 L. monocytogenes ∆hmgR 
pPL2-gcpE 
(Phyper-HPB) pPL2x 
gcpE from HPB2262 complemented with 
Phyper promoter 
EDL255 L. monocytogenes ∆hmgR 
pPL2-lytB 
(10403S) pPL2x 
lytB from 10403S complemented with ~200 bp 
upstream promoter 
EDL256 L. monocytogenes ∆hmgR pPL2-lytB (FSL) pPL2x 
lytB from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL257 L. monocytogenes ∆hmgR pPL2-lytB (HPB) pPL2x 
lytB from HPB2262 complemented with ~200 
bp upstream promoter 
EDL258 L. monocytogenes ∆hmgR 
pPL2-lytB 
(Phyper-10403S) pPL2x 
lytB from 10403S complemented with Phyper 
promoter 
EDL259 L. monocytogenes ∆hmgR 
pPL2-lytB 
(Phyper-FSL,HPB) pPL2x 
lytB from FSL N1-017 complemented with 
Phyper promoter 
EDL260 L. monocytogenes ∆gcpE hly::Tn917 
pPL2-gcpE 
(10403S) pPL2x 
EDL189 with gcpE from 10403S 
complemented with ~200 bp upstream 
promoter 
EDL261 L. monocytogenes ∆gcpE hly::Tn917 pPL2-gcpE (FSL) pPL2x 
EDL189 with gcpE from FSL N1-017 
complemented with ~200 bp upstream 
promoter 
EDL262 L. monocytogenes ∆gcpE hly::Tn917 pPL2-gcpE (HPB) pPL2x 
EDL189 with gcpE from HPB2262 
complemented with ~200 bp upstream 
promoter 
EDL263 L. monocytogenes ∆gcpE hly::Tn917 
pPL2-gcpE 
(Phyper-HPB) pPL2x 
EDL189 with gcpE from HPB2262 
complemented with Phyper promoter 
EDL264 L. monocytogenes ∆lytB hly::Tn917 
pPL2-lytB 
(10403S) pPL2x 
EDL190 with lytB from 10403S complemented 
with ~200 bp upstream promoter 
EDL265 L. monocytogenes ∆lytB hly::Tn917 pPL2-lytB (FSL) pPL2x 
EDL190 with lytB from FSL N1-017 
complemented with ~200 bp upstream 
promoter 
EDL266 L. monocytogenes ∆lytB hly::Tn917 pPL2-lytB (HPB) pPL2x 
EDL190 with lytB from HPB2262 
complemented with ~200 bp upstream 
promoter 
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EDL267 L. monocytogenes ∆lytB hly::Tn917 
pPL2-lytB 
(Phyper-10403S) pPL2x 
EDL190 with lytB from 10403S complemented 
with Phyper promoter 
EDL268 L. monocytogenes ∆lytB hly::Tn917 
pPL2-lytB 
(Phyper-FSL,HPB) pPL2x 
EDL190 with lytB from FSL N1-017 
complemented with Phyper promoter 
EDL269 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S) pPL2x 
gcpE from 10403S complemented with ~200 
bp upstream promoter 
EDL270 L. monocytogenes ∆hmgR ∆gcpE pPL2-gcpE (FSL) pPL2x 
gcpE from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL271 L. monocytogenes ∆hmgR ∆gcpE pPL2-gcpE (HPB) pPL2x 
gcpE from HPB2262 complemented with ~200 
bp upstream promoter 
EDL272 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(Phyper-HPB) pPL2x 
gcpE from HPB2262 complemented with 
Phyper promoter 
EDL273 L. monocytogenes ∆hmgR ∆lytB 
pPL2-lytB 
(10403S) pPL2x 
lytB from 10403S complemented with ~200 bp 
upstream promoter 
EDL274 L. monocytogenes ∆hmgR ∆lytB pPL2-lytB (FSL) pPL2x 
lytB from FSL N1-017 complemented with 
~200 bp upstream promoter 
EDL275 L. monocytogenes ∆hmgR ∆lytB pPL2-lytB (HPB) pPL2x 
lytB from HPB2262 complemented with ~200 
bp upstream promoter 
EDL276 L. monocytogenes ∆hmgR ∆lytB 
pPL2-lytB 
(Phyper-10403S) pPL2x 
lytB from 10403S complemented with Phyper 
promoter 
EDL277 L. monocytogenes ∆hmgR ∆lytB 
pPL2-lytB 
(Phyper-FSL,HPB) pPL2x 
lytB from FSL N1-017 complemented with 
Phyper promoter 
EDL278 E. coli (SM10)  
pPL2-gcpE 
(Phyper-10403S) pPL2x 
gcpE from 10403S complemented with Phyper 
promoter 
EDL279 L. monocytogenes ∆gcpE 
pPL2-gcpE 
(10403S) pPL2x 
EDL011 with gcpE from 10403S 
complemented with ~200 bp upstream 
promoter 
EDL280 L. monocytogenes ∆gcpE pPL2-gcpE (FSL) pPL2x 
EDL011 with gcpE from FSL N1-017 
complemented with ~200 bp upstream 
promoter 
EDL281 L. monocytogenes ∆gcpE pPL2-gcpE (HPB) pPL2x 
EDL011 with gcpE from HPB2262 
complemented with ~200 bp upstream 
promoter 
EDL282 L. monocytogenes ∆gcpE 
pPL2-gcpE 
(Phyper-HPB) pPL2x 
EDL011 with gcpE from HPB2262 
complemented with Phyper promoter 
EDL283 L. monocytogenes ∆lytB 
pPL2-gcpE 
(10403S) pPL2x 
EDL012 with gcpE from 10403S 
complemented with ~200 bp upstream 
promoter 
EDL284 L. monocytogenes ∆lytB pPL2-gcpE (FSL) pPL2x 
EDL012 with gcpE from FSL N1-017 
complemented with ~200 bp upstream 
promoter 
EDL285 L. monocytogenes ∆lytB pPL2-gcpE (HPB) pPL2x 
EDL012 with gcpE from HPB2262 
complemented with ~200 bp upstream 
promoter 
EDL286 L. monocytogenes ∆lytB 
pPL2-gcpE 
(Phyper-HPB) pPL2x 
EDL012 with gcpE from HPB2262 
complemented with Phyper promoter 
EDL287 L. monocytogenes ∆gcpE 
pPL2-gcpE 
(Phyper-10403S) pPL2x 
gcpE from 10403S complemented with Phyper 
promoter 
EDL288 L. monocytogenes ∆lytB 
pPL2-gcpE 
(Phyper-10403S) pPL2x 
gcpE from 10403S complemented with Phyper 
promoter 
EDL289 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(Phyper-10403S) pPL2x 
gcpE from 10403S complemented with Phyper 
promoter 
EDL290 L. monocytogenes ∆hmgR ∆lytB 
pPL2-gcpE 
(Phyper-10403S) pPL2x 
gcpE from 10403S complemented with Phyper 
promoter 
EDL291 E. coli (SM10)  
pPL2-gcpE 
(P10403S FSL 
N1-017) pPL2x  
EDL292 E. coli (SM10)  
pPL2-gcpE 
(P10403S 
HPB2262) pPL2x  
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EDL293 E. coli (SM10)  
pPL2-gcpE (PFSL 
10403S) pPL2x  
EDL294 E. coli (SM10)  
pPL2-gcpE (PHPB 
10403S) pPL2x  
EDL295 L. monocytogenes ∆hmgR 
pPL2-gcpE 
(Phyper-10403S) pPL2x  
EDL296 L. monocytogenes ∆hmgR 
pPL2-gcpE 
(P10403S FSL 
N1-017) pPL2x  
EDL297 L. monocytogenes ∆hmgR 
pPL2-gcpE 
(P10403S 
HPB2262) pPL2x  
EDL298 L. monocytogenes ∆hmgR 
pPL2-gcpE (PFSL 
10403S) pPL2x  
EDL299 L. monocytogenes ∆hmgR 
pPL2-gcpE (PHPB 
10403S) pPL2x  
EDL300 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(P10403S FSL 
N1-017) pPL2x  
EDL301 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(P10403S 
HPB2262) pPL2x  
EDL302 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE (PFSL 
10403S) pPL2x  
EDL303 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE (PHPB 
10403S) pPL2x  
EDL304 E. coli (SM10)  
pPL2-gcpE 
(P10403S 
10403S+FSL N1-
017) pPL2x  
EDL305 E. coli (SM10)  
pPL2-lytB 
(P10403S + FSL 
N1-017) pPL2x KN 
EDL306 E. coli (SM10)  
pPL2-lytB 
(P10403S + 
HPB2262) pPL2x KN 
EDL307 E. coli (SM10)  
pPL2-lytB (P FSL 
+ 10403S) pPL2x KN 
EDL308 E. coli (SM10)  
pPL2-gcpE 
(10403S, 
K291T/E293K/V29
4A) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL309 E. coli (SM10)  
pPL2-gcpE 
(10403S, 
I343V/D344E) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL310 E. coli (SM10)  
pPL2-gcpE 
(10403S, 
F357Y/V359E) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL311 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, 
I343V/D344E) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL312 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, 
F357Y/V359E) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL313 L. monocytogenes ∆hmgR ∆lytB 
pPL2-lytB 
(P10403S + FSL 
N1-017) pPL2x KN 
EDL314 L. monocytogenes ∆hmgR ∆lytB 
pPL2-lytB 
(P10403S + 
HPB2262) pPL2x KN 
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EDL315 L. monocytogenes ∆hmgR ∆lytB 
pPL2-lytB (P FSL 
+ 10403S) pPL2x KN 
EDL316 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(P10403S 
10403S+FSL N1-
017) pPL2x 
Chimera of 10403S and FSL (C-terminal) 
protein, starting at 250 AA 
EDL317 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, 
K291T/E293K/V29
4A) pPL2x  
EDL318 L. monocytogenes ∆hmgR ∆lytB 
pPL2-gcpE 
(10403S) pPL2x  
EDL319 L. monocytogenes ∆hmgR ∆lytB 
pPL2-lytB (P HPB 
+ 10403S) pPL2x KN 
EDL320 E. coli (SM10)  
pPL2-gcpE 
(10403S, 
K291T/E293K/V29
4A/I343V/D344E) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL321 E. coli (SM10)  
pPL2-gcpE 
(10403S, 
K291T/E293K/V29
4A/F357Y/V359E) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL322 E. coli (SM10)  
pPL2-gcpE 
(10403S, K291T) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL323 E. coli (SM10)  
pPL2-gcpE 
(10403S, E293K) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL324 E. coli (SM10)  
pPL2-gcpE 
(10403S, V294A) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL325 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, K291T) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL326 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, E293K) pPL2x *** Accidentally complemented in lytB? 
EDL327 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, V294A) pPL2x 
Point mutations in gcpE to match 10403S 
more closely with clinical isolates 
EDL328 L. monocytogenes 
∆hmgR 
fmnB::Tn917   hmgR strain with FLEET mutants (lmo2636) 
EDL329 L. monocytogenes 
∆hmgR 
ndh2::Tn917   hmgR strain with FLEET mutants (lmo2638) 
EDL330 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, 
K291T/E293K/V29
4A/I343V/D344E) pPL2x  
EDL331 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-gcpE 
(10403S, 
K291T/E293K/V29
4A/F357Y/V359E) pPL2x  
EDL332 E. coli (SM10)  
pKSV7-gcpE 
(K291T/E293K/V2
94A) pKSV7x 
Complements gcpE (K291T/E293K/V294A) 
onto the chromosome 
EDL333 L. monocytogenes pActA(999)-hmgS   
Complements hmgS under mutated pActA 
(from Chen, on the chromosome) 
EDL334 L. monocytogenes 
gcpE 
(K291T/E293K/V29
4A)   
Point mutations in gcpE 
(K291T/E293K/V294A) complemented onto 
the chromosome 
EDL335 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A)    
EDL336 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) lisK106A>G 
lmo1389::himar1   
Adds lisK suppressor mutation into improved 
gcpE background 
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EDL337 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) lisK826G>A 
lmo1389::himar1   
Adds lisK suppressor mutation into improved 
gcpE background 
EDL338 L. monocytogenes ∆hmgR 
pPL2-gcpE 
(10403S, E293K)  *** Accidentally complemented in lytB? 
EDL339 E. coli (SM10)  
pPL2-Phyper-
iscSUAX-hSCBA 
(E. coli) pPL2x 
Contains ISC operon from K-12 E. coli to see if 
it complements aerobic ∆hmgR growth 
EDL340 E. coli (SM10)  
pPL2-Pnative-
sufCDSUB pPL2x 
Contains sufCDSUB operon from B subtilis to 
see if it complements aerobic ∆hmgR growth 
EDL341 E. coli (SM10)  
pPL2-Phyper-
sufCDSUB pPL2x 
Contains sufCDSUB operon from B subtilis to 
see if it complements aerobic ∆hmgR growth 
EDL342 E. coli (SM10)  pKSV7-lytB (FSL) pKSV7x 
Complements gcpE (K291T/E293K/V294A) 
onto the chromosome 
EDL343 L. monocytogenes ∆hmgR 
pPL2-Phyper-
iscSUAX-hSCBA 
(E. coli) pPL2x 
Contains ISC operon from K-12 E. coli to see if 
it complements aerobic ∆hmgR growth 
EDL344 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-Phyper-
iscSUAX-hSCBA 
(E. coli) pPL2x 
Contains ISC operon from K-12 E. coli to see if 
it complements aerobic ∆hmgR growth 
EDL345 L. monocytogenes ∆hmgR 
pPL2-Pnative-
sufCDSUB pPL2x 
Contains sufCDSUB operon from B subtilis to 
see if it complements aerobic ∆hmgR growth 
EDL346 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-Pnative-
sufCDSUB pPL2x 
Contains sufCDSUB operon from B subtilis to 
see if it complements aerobic ∆hmgR growth 
EDL347 L. monocytogenes ∆hmgR 
pPL2-Phyper-
sufCDSUB pPL2x 
Contains sufCDSUB operon from B subtilis to 
see if it complements aerobic ∆hmgR growth 
EDL348 L. monocytogenes ∆hmgR ∆gcpE 
pPL2-Phyper-
sufCDSUB pPL2x 
Contains sufCDSUB operon from B subtilis to 
see if it complements aerobic ∆hmgR growth 
EDL349 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB    
EDL350 L. monocytogenes 
∆hmgR 
lmo1956::Tn   Transposon in Fur regulator 
EDL351 L. monocytogenes 
∆hmgR ∆gcpE 
lmo1956::Tn   Transposon in Fur regulator 
EDL352 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB 
pPL2-lytB 
(10403S)  
Complements varying lytB genes in gcpE* 
background 
EDL353 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB pPL2-lytB (FSL)  
Complements varying lytB genes in gcpE* 
background 
EDL354 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB pPL2-lytB (HPB)  
Complements varying lytB genes in gcpE* 
background 
EDL355 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB 
pPL2-lytB 
(Phyper-10403S)  
Complements varying lytB genes in gcpE* 
background 
EDL356 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB 
pPL2-lytB 
(Phyper-FSL,HPB)  
Complements varying lytB genes in gcpE* 
background 
EDL357 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB 
pPL2-lytB 
(P10403S + FSL 
N1-017)  
Complements varying lytB genes in gcpE* 
background 
EDL358 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB 
pPL2-lytB 
(P10403S + 
HPB2262)  
Complements varying lytB genes in gcpE* 
background 
EDL359 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) ∆lytB 
pPL2-lytB (P FSL 
+ 10403S)  
Complements varying lytB genes in gcpE* 
background 
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EDL360 E. coli (SM10)  
pKSV7-
∆gcpE+kanR pKSV7x 
EDL009 with kanR cassette added in-frame 
after stop codon, for genetic linkage 
experiment 
EDL361 E. coli (SM10)  
pKSV7-∆sufSU 
(lmo2412/2413) pKSV7x 
pKSV7 to delete sufSU (lmo2412/2413) in 
frame, without kanR cassette 
EDL362 E. coli (SM10)  
pKSV7-
∆sufSU+KanR 
inverted 
(lmo2412/2413) pKSV7x 
pKSV7 to delete lmo2412/2413 with kanR 
cassette added backwards 
EDL363 E. coli (SM10)  
pPL2-lytB (PHPB 
+ 10403S) pPL2x  
EDL364 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) lytB (FSL)   
hmgR knockout with manipulated gcpE and lytB 
from FSL N1-017 
EDL365 L. monocytogenes 
gcpE 
(K291T/E293K/V29
4A) hly::Tn917    
EDL366 E. coli (SM10)  
pPL2-Phy-lytB 
(10403S/FSL 
chimera) pPL2x Split made at AA 221 
EDL367 E. coli (SM10)  
pPL2-Phy-lytB 
(HPB/10403S 
chimera) pPL2x Split made at AA 221 
EDL368 E. coli (SM10)  pKSV7-∆hmgR pKSV7x Remade, correct plasmid to delete hmgR 
EDL369 E. coli (SM10)  
pKSV7-
∆hmgR+KanR pKSV7x 
Makes hmgR deletion with KanR cassette 
fused directly behind 
EDL370 E. coli (SM10)  
pKSV7-
HmgR+KanR pKSV7x 
Keeps hmgR gene with KanR cassette fused 
directly behind 
EDL373 L. monocytogenes    DP-L7000 
EDL374 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) 
pPL2-Phyper-
iscSUAX-hSCBA 
(E. coli) pPL2x  
EDL375 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) 
pPL2-Pnative-
sufCDSUB pPL2x  
EDL376 L. monocytogenes 
∆hmgR gcpE 
(K291T/E293K/V29
4A) 
pPL2-Phyper-
sufCDSUB pPL2x  
EDL377 L.monocytogenes  
pPL2-Phyper-
sufCDSUB pPL2x  
EDL378 E. coli (XL1 Blue)   pMV306 Integrating vector for cloning in M. tuberculosis 
EDL379 L. monocytogenes  
pPL2-Phyper-
iscSUAX-hSCBA 
(E. coli) pPL2x 
Contains ISC operon from K-12 E. coli to see if 
it complements aerobic ∆hmgR growth 
EDL380 L. monocytogenes ∆gcpE ∆lytB   Nonmevalonate pathway double knockout 
EDL381 L. monocytogenes 
gcpE* 
(K291T/E293K/V29
4A) ∆lytB   
LytB knockout with gcpE* chromosomal 
mutations 
EDL382 E. coli (SM 10)  
pKSV7 - ∆SufSU + 
KanR pKSV7 
Makes hmgR deletion with KanR casette fused 
directly behind. No stop codon 
EDL383 L. monocytogenes 
∆actA pActA(999)-
hmgS   
Complements hmgS under mutated pActA 
(from Chen, on the chromosome); unknown 
actA deletion 
EDL384 E coli (SM 10)  
pPL2 - Prha - suf 
(lmo native) pPL2x  
EDL385 E. coli (SM 10)  
pPL2 - Phyper - 
suf (lmo native) pPL2x 
NOPE but i'm keeping the placeholder in the 
lab inventory 
EDL386 L. monocytogenes WT 
pPL2 - Phyper 
suf(lmo native) pPL2x 
NOPE, BUT i'm keeping the placeholder for 
now. 
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EDL387 L. monocytogenes ∆hmgR 
pPL2 - Phyper - 
suf(lmo native) pPL2x NOPE but keeping placeholder 
EDL388 L. monocytogenes WT  
pPL2 - Prhamnose 
- suf (lmo native) pPL2x 
two frozen in bottom of box waiting for further 
screening 
EDL389 L. monocytogenes ∆hmgR 
pPL2 - Prhamnose 
- suf (lmo native) pPL2x 
two frozen in bottom of box waiting for further 
screening 
 
 
